Split (1)

train · 22k rows

Record stringlengths 1 197k
<\|newrecord\|> nctId: NCT06307743 id: RAPID-SAVE briefTitle: Rapid Local Ischemic Postconditioning in Acute Ischemic Stroke acronym: RAPID-SAVE overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-06-15 date: 2025-09-15 date: 2024-03-13 date: 2024-03-13 name: Shanghai Jiao Tong University Affiliated Sixth People's Hospital class: OTHER name: Zhangzhou Municipal Hospital of Fujian Province name: Shanghai East Hospital name: First People's Hospital of Hangzhou name: RenJi Hospital briefSummary: The objective of this clinical trial is to determine whether rapid local ischemic postconditioning (RL-IPostC) is effective in preventing brain edema and safe in acute ischemic stroke (AIS) patients treated with mechanical thrombectomy. In this trial, researchers will block antegrade cerebral blood flow temporarily by the way of balloon inflation/deflation in AIS patients immediately after revascularization. It makes the ischemic reperfusion brain tissue have a capacity of adaptation through intermittent blood flow restoration. Researchers will evaluate the protective role and safety of different duration of balloon inflation/deflation. The optimal postconditioning intervention dose will be determined for further confirmative investigation. conditions: Acute Ischemic Stroke conditions: Mechanical Thrombectomy conditions: Ischemic Postconditioning conditions: Brain Edema studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 135 type: ESTIMATED name: rapid local ischemic postconditioning measure: Number of Participants without clinically meaningful cerebral swelling, significant increase in infarct volume from baseline and intervention-related serious adverse events. measure: Rate of participants without clinically meaningful cerebral swelling measure: Rate of participants with significant increase in infarct volume from baseline or intervention-related serious adverse events. measure: Change in volume of cerebrospinal fluid (∆CSF72) at 72 hours measure: Change of net water uptake (∆NWU24) at 24 hours measure: Change of net water uptake (∆NWU72) at 72 hours measure: Midline shift at 24 hours measure: Midline shift at 72 hours measure: Change of NIHSS at 24 hours measure: Early therapeutic response to treatment measure: Good outcome at 90 days measure: Excellent outcome at 90 days sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307730 id: CHSD_0033_GERIATRIE briefTitle: Application of the Recommendations of the SPLIF (French Society of Infectious Pathology) in a Geriatric Population on the Duration of Treatment for Bacterial Pneumonia overallStatus: COMPLETED date: 2023-01-02 date: 2023-04-30 date: 2023-04-30 date: 2024-03-13 date: 2024-03-13 name: Centre Hospitalier de Saint-Denis class: OTHER briefSummary: Pneumopathy is the leading cause of death from infectious disease in the elderly. Prior to 2021, the recommended duration of antibiotic therapy for pneumonia, in adults, was 7 days.
Two theses have shown that these recommendations were poorly applied in geriatric services. Indeed, the duration of treatment exceeded 7 days, and less than 30% of antibiotic antibiotic treatments were re-evaluated at 72 hours.
In 2021, the SPLIF ( published new recommendations reducing this duration to 5 days in the event of clinical improvement observed on the 3rd day of treatment. These new recommendations are based on studies, in which the average age of participants was 65 years. However, the average age of patients in geriatric short-stay departments is 84.7 years.
In addition, the geriatric population is characterized by immunosenescence, pulmonary vulnerability and undernutrition, raising questions about the validity of these recommendations in the geriatric population.
The investigators offer a monocentric, retrospective, observational study of the geriatric hospital Casanova to assess the application of SPLIF recommendations in the geriatric population. conditions: Pneumonia, Bacterial conditions: Pneumopathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 35 type: ACTUAL measure: Sex measure: Age measure: Weight measure: Phone Number measure: Origins measure: Autonomy in daily life's score before hospitalisation measure: Charlson's morbidity score sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hopitalier de Saint-Denis city: Saint-Denis state: Seine Saint Denis zip: 93200 country: France lat: 48.93326 lon: 2.36666 hasResults: False
<\|newrecord\|> nctId: NCT06307717 id: PLAGH-DA-002 briefTitle: Effects of Volatile Anaesthetics on Incidence of Postoperative Depression and Anxiety in Elderly Patients overallStatus: COMPLETED date: 2020-04-01 date: 2021-10-31 date: 2022-04-30 date: 2024-03-13 date: 2024-04-10 name: Chinese PLA General Hospital class: OTHER name: Beijing Tsinghua Changgeng Hospital name: Peking University First Hospital name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School name: Xiangya Hospital of Central South University name: Beijing Anzhen Hospital name: Central South University name: Peking University People's Hospital name: Zhejiang University name: Fudan University name: Sun Yat-sen University name: Wuhan Union Hospital, China name: China-Japan Friendship Hospital name: The Affiliated Hospital Of Guizhou Medical University name: First Affiliated Hospital of Xinjiang Medical University name: First Affiliated Hospital of Guangxi Medical University name: Taihe Hospital briefSummary: This study is a retrospective analysis of a large-scale multicentre prospective cohort study that investigates the impact of volatile anaesthetics on the incidence of postoperative depression and anxiety among elderly patients. conditions: Cohort Studies studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 8000 type: ACTUAL name: volatile anaesthetic (sevoflurane, isoflurane, desflurane) measure: Depression measure: Anxiety sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Chinese PLA General Hospital city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
<\|newrecord\|> nctId: NCT06307704 id: LUSPEEPORRPC briefTitle: Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients overallStatus: RECRUITING date: 2024-03 date: 2024-09 date: 2024-09 date: 2024-03-13 date: 2024-03-15 name: Nazmy Edward Seif class: OTHER briefSummary: There is an increasing trend in the use of robotic-assisted radical prostatectomy or cystectomy (RARPC).
Preventing lung atelectasis without inducing overdistention of the lung is challenging. Many studies tried to optimize PEEP titration by using methods such as dead space fraction guided and static pulmonary compliance directed techniques, or by using electrical impedance tomography. However, the use of these methods is limited by inaccuracy and the need for sophisticated devices.
Bedside Lung ultrasound is fast, easy and economic technique that is gaining interest in the operating room. Ultrasound-guided PEEP titration has been used in bariatric surgeries (different position and usually shorter procedure time) and proved effective in improving oxygenation, compliance and reducing the incidence of postoperative pulmonary atelectasis and hypoxia without causing hemodynamic instability.
The aim of this study is to evaluate the effectiveness of intraoperative individualized lung ultrasound-guided stepwise PEEP optimization in patients undergoing RARPC on oxygenation, intraoperative and early postoperative pulmonary complications. conditions: Prostate Cancer conditions: Urinary Bladder Cancer conditions: Surgery conditions: Positive End Expiratory Pressure conditions: Lung Ultrasound studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 88 type: ESTIMATED name: Lung Ultrasound - guided Stepwise PEEP name: Standard Ventilation Protocol measure: Post-operative lung consolidation sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cairo University Hospitals status: RECRUITING city: Cairo country: Egypt name: Mustafa E Mohamed, MD role: CONTACT phone: 01140806330 phoneExt: +2 email: mustafaemam931@gmail.com name: Nazmy S Mikhael, MD role: CONTACT phone: 01227400808 phoneExt: +2 email: nazmy.edwar.seif@gmail.com lat: 30.06263 lon: 31.24967 hasResults: False
<\|newrecord\|> nctId: NCT06307691 id: 11423 briefTitle: Clinical and Radiographic Evaluation of Immediate Implant Placement Using Osseodensification Versus Traditional Drilling Protocol overallStatus: RECRUITING date: 2024-03-06 date: 2025-12-20 date: 2026-12-20 date: 2024-03-13 date: 2024-03-19 name: Cairo University class: OTHER briefSummary: For the purpose of the study, patients will be divided into two groups, i.e., Group A and Group B. In Group (A), 14 immediate implants will be placed using traditional drilling technique, while in Group (B), 14 immediate implants will be placed using OD drilling technique Osseodensification is a system for implant osteotomy preparation, it compresses the cancellous bone around the revolving drills. It largely improves low bone volume by physically increasing the interlocking between the bone and the implant surface. The Densah burs enhances bone density while generating the least amount of heat.
Traditional oversized drilling is the regular manufacturer recommended technique of drilling. It functions by cutting the bone during osteotomy preparation by sharp fluted drills. The undersizing of the preparation allows the implant to partially compact the bone during insertion.
The objective of the current study is to compare between osseodensification drilling protocol versus traditional undersized drilling protocol in immediate implant placement in anterior maxillary region in terms of implant stability. conditions: Implant Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: patients will be randomly selected into either group using computer generated randomization using (www.randomizer.org). The randomized numbers will be allocated to each site in each patient and will be placed in opaque, sealed and sequentially numbered envelopes. patients will be randomly allocated to test and control groups using randomization schedule.
Masking/blinding:
* Participants will be blinded
* Blinding of the operator will be blinded
* The outcome assessor will be blinded
* The biostatistician will be blinded whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 26 type: ESTIMATED name: Conventional drilling name: Osseodensification drilling measure: Implant stability quotient (ISQ) measure: Crestal bone level sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Faculty of Dentistry Cairo University status: RECRUITING city: Cairo country: Egypt name: Omar M Ibrahim, master role: CONTACT phone: 01000953710 phoneExt: 002 email: omar_ibrahim@dentistry.cu.edu.eg name: Omnia K Tawfik, PhD role: CONTACT phone: 01006002618 email: omnia.tawfik@dentistry.cu.edu.eg lat: 30.06263 lon: 31.24967 hasResults: False
<\|newrecord\|> nctId: NCT06307678 id: AtaturkU-DHF-MS-01 briefTitle: Effect of Calcium Silicate Based Root Canal Medicament on Inflammatory Mediators overallStatus: COMPLETED date: 2023-07-07 date: 2023-12-10 date: 2023-12-10 date: 2024-03-13 date: 2024-03-13 name: Ataturk University class: OTHER briefSummary: Calcium hydroxide is generally preferred in endodontics as an intracanal medicament because of its antimicrobial and biological effects. However, the antimicrobial effect of calcium hydroxide is limited.
The aim of this study was to investigate the effects of calcium silicate-based root canal medicament on the release of RANKL/OPG, TNF-α, PGE-2 and TGF-β1 in root canal treated teeth with periapical lesions. conditions: Periapical; Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: two groups: group 1 calcium hydroxide based medicament (control group) group 2: calcium silicate based medicament primaryPurpose: TREATMENT masking: SINGLE maskingDescription: outcome assessments have performed by a investigator who was blinded to groups. whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: Calcium Hydroxide name: Calcium Silicate measure: preoperative and postoperative levels of RANKL/OPG ratio measure: preoperative and postoperative levels of prostaglandinE2 (PGE2) ratio measure: preoperative and postoperative levels of TNF alpha ratio measure: preoperative and postoperative levels of TGF beta ratio measure: dependent variables (sex, age, teeth number, smoking habit) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ataturk University city: Erzurum zip: 25240 country: Turkey lat: 39.90861 lon: 41.27694 hasResults: False
<\|newrecord\|> nctId: NCT06307665 id: D6934C00001 briefTitle: Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma acronym: ACADIA overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2027-10-13 date: 2027-10-13 date: 2024-03-13 date: 2024-04-09 name: AstraZeneca class: INDUSTRY name: Parexel briefSummary: The purpose of this study is to compare the budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI) administered as needed on severe asthma exacerbations in adolescent participants aged 12 to \< 18 years with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year. conditions: Asthma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 440 type: ESTIMATED name: BDA MDI name: AS MDI measure: Annualized rate of severe asthma exacerbations (AAER) measure: Time to first (TTF) severe asthma exacerbation measure: Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma measure: Number of participants with adverse events (AEs) and severe adverse events (SAEs) measure: Maximum Observed Concentration (Cmax) measure: Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast) measure: Area under plasma concentration-time curve from time 0 to infinity (AUCinf) measure: Time to reach maximum concentration following drug administration (Tmax) measure: Time to reach maximum concentration following drug administration (Tlast) measure: Terminal elimination half-life (t½λz) measure: Terminal elimination rate constant (λz) measure: Apparent total body clearance (CL/F) measure: Apparent volume of distribution based on the terminal phase (Vz/F) sex: ALL minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD facility: Research Site city: White Marsh state: Maryland zip: 21162 country: United States lat: 39.38372 lon: -76.43218 hasResults: False
<\|newrecord\|> nctId: NCT06307652 id: D6402C00012 briefTitle: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function acronym: BalanceD-HF overallStatus: NOT_YET_RECRUITING date: 2024-04-12 date: 2027-06-11 date: 2027-06-11 date: 2024-03-13 date: 2024-03-13 name: AstraZeneca class: INDUSTRY briefSummary: This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events. conditions: Heart Failure and Impaired Kidney Function studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 4800 type: ESTIMATED name: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg name: balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg name: dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin measure: Time to first occurrence of any of the components of the composite of: •CV death •HF hospitalisation •HF event without hospitalisation measure: Total occurrences (first and recurrent) of the components of the composite of: •CV death •HF hospitalisation •HF event without hospitalisation measure: Total occurrences (first and recurrent) of HF hospitalisations measure: Time to CV death measure: The hierarchical composite endpoint of death from any cause, total HF events, and change from baseline in KCCQ total symptom score to 24-week post-randomisation measure: Time to death from any cause sex: ALL minimumAge: 18 Years maximumAge: 130 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site city: Alexander City state: Alabama zip: 35010 country: United States lat: 32.94401 lon: -85.95385 facility: Research Site city: Fairhope state: Alabama zip: 36532 country: United States lat: 30.52297 lon: -87.90333 facility: Research Site city: Little Rock state: Arkansas zip: 72205 country: United States lat: 34.74648 lon: -92.28959 facility: Research Site city: Los Angeles state: California zip: 90089 country: United States lat: 34.05223 lon: -118.24368 facility: Research Site city: Newport Beach state: California zip: 92663 country: United States lat: 33.61891 lon: -117.92895 facility: Research Site city: San Diego state: California zip: 92123 country: United States lat: 32.71533 lon: -117.15726 facility: Research Site city: Santa Ana state: California zip: 92704 country: United States lat: 33.74557 lon: -117.86783 facility: Research Site city: Thousand Oaks state: California zip: 91360 country: United States lat: 34.17056 lon: -118.83759 facility: Research Site city: Altamonte Springs state: Florida zip: 32701 country: United States lat: 28.66111 lon: -81.36562 facility: Research Site city: Clearwater state: Florida zip: 33756 country: United States lat: 27.96585 lon: -82.8001 facility: Research Site city: Jacksonville state: Florida zip: 32209 country: United States lat: 30.33218 lon: -81.65565 facility: Research Site city: Miami state: Florida zip: 33133 country: United States lat: 25.77427 lon: -80.19366 facility: Research Site city: Saint Augustine state: Florida zip: 32086 country: United States lat: 29.89469 lon: -81.31452 facility: Research Site city: Atlanta state: Georgia zip: 30303 country: United States lat: 33.749 lon: -84.38798 facility: Research Site city: Tucker state: Georgia zip: 30084 country: United States lat: 33.85455 lon: -84.21714 facility: Research Site city: Chicago state: Illinois zip: 60637 country: United States lat: 41.85003 lon: -87.65005 facility: Research Site city: Hazel Crest state: Illinois zip: 60429 country: United States lat: 41.5717 lon: -87.69449 facility: Research Site city: Hammond state: Indiana zip: 46324 country: United States lat: 41.58337 lon: -87.50004 facility: Research Site city: Munster state: Indiana zip: 46321 country: United States lat: 41.56448 lon: -87.51254 facility: Research Site city: Richmond state: Indiana zip: 47374 country: United States lat: 39.82894 lon: -84.89024 facility: Research Site city: Wichita state: Kansas zip: 67218 country: United States lat: 37.69224 lon: -97.33754 facility: Research Site city: Wichita state: Kansas zip: 67226 country: United States lat: 37.69224 lon: -97.33754 facility: Research Site city: Louisville state: Kentucky zip: 40202 country: United States lat: 38.25424 lon: -85.75941 facility: Research Site city: Alexandria state: Louisiana zip: 71301 country: United States lat: 31.31129 lon: -92.44514 facility: Research Site city: Shreveport state: Louisiana zip: 71105 country: United States lat: 32.52515 lon: -93.75018 facility: Research Site city: Augusta state: Maine zip: 04330 country: United States lat: 44.31062 lon: -69.77949 facility: Research Site city: Dearborn state: Michigan zip: 48126 country: United States lat: 42.32226 lon: -83.17631 facility: Research Site city: Flint state: Michigan zip: 48504 country: United States lat: 43.01253 lon: -83.68746 facility: Research Site city: Saint Paul state: Minnesota zip: 55102 country: United States lat: 44.94441 lon: -93.09327 facility: Research Site city: Kansas City state: Missouri zip: 64128 country: United States lat: 39.09973 lon: -94.57857 facility: Research Site city: Lincoln state: Nebraska zip: 68506 country: United States lat: 40.8 lon: -96.66696 facility: Research Site city: Somerset state: New Jersey zip: 08873 country: United States lat: 40.4976 lon: -74.48849 facility: Research Site city: Bronx state: New York zip: 10455 country: United States lat: 40.84985 lon: -73.86641 facility: Research Site city: Buffalo state: New York zip: 14215 country: United States lat: 42.88645 lon: -78.87837 facility: Research Site city: Chapel Hill state: North Carolina zip: 27517 country: United States lat: 35.9132 lon: -79.05584 facility: Research Site city: Greensboro state: North Carolina zip: 27405 country: United States lat: 36.07264 lon: -79.79198 facility: Research Site city: Cincinnati state: Ohio zip: 45267 country: United States lat: 39.12713 lon: -84.51435 facility: Research Site city: Maumee state: Ohio zip: 43537 country: United States lat: 41.56283 lon: -83.65382 facility: Research Site city: Abington state: Pennsylvania zip: 19001 country: United States lat: 40.12067 lon: -75.11795 facility: Research Site city: Camp Hill state: Pennsylvania zip: 17011 country: United States lat: 40.23981 lon: -76.91997 facility: Research Site city: Hershey state: Pennsylvania zip: 17033 country: United States lat: 40.28592 lon: -76.65025 facility: Research Site city: Horsham state: Pennsylvania zip: 19044 country: United States lat: 40.17844 lon: -75.12851 facility: Research Site city: Providence state: Rhode Island zip: 02908 country: United States lat: 41.82399 lon: -71.41283 facility: Research Site city: Rapid City state: South Dakota zip: 57701 country: United States lat: 44.08054 lon: -103.23101 facility: Research Site city: Jackson state: Tennessee zip: 38301 country: United States lat: 35.61452 lon: -88.81395 facility: Research Site city: Knoxville state: Tennessee zip: 37916 country: United States lat: 35.96064 lon: -83.92074 facility: Research Site city: Memphis state: Tennessee zip: 38128 country: United States lat: 35.14953 lon: -90.04898 facility: Research Site city: Nashville state: Tennessee zip: 37212 country: United States lat: 36.16589 lon: -86.78444 facility: Research Site city: Tullahoma state: Tennessee zip: 37388 country: United States lat: 35.36202 lon: -86.20943 facility: Research Site city: Cypress state: Texas zip: 77429 country: United States lat: 29.96911 lon: -95.69717 facility: Research Site city: El Paso state: Texas zip: 79905 country: United States lat: 31.75872 lon: -106.48693 facility: Research Site city: Houston state: Texas zip: 77025 country: United States lat: 29.76328 lon: -95.36327 facility: Research Site city: Houston state: Texas zip: 77090 country: United States lat: 29.76328 lon: -95.36327 facility: Research Site city: Katy state: Texas zip: 77493 country: United States lat: 29.78579 lon: -95.8244 facility: Research Site city: Odessa state: Texas zip: 79761 country: United States lat: 31.84568 lon: -102.36764 facility: Research Site city: Sherman state: Texas zip: 75092 country: United States lat: 33.63566 lon: -96.60888 facility: Research Site city: Falls Church state: Virginia zip: 22042 country: United States lat: 38.88233 lon: -77.17109 facility: Research Site city: Newport News state: Virginia zip: 23606 country: United States lat: 37.08339 lon: -76.46965 facility: Research Site city: Buenos Aires zip: 1425DES country: Argentina lat: -34.61315 lon: -58.37723 facility: Research Site city: Buenos Aires zip: C1056ABJ country: Argentina lat: -34.61315 lon: -58.37723 facility: Research Site city: Buenos Aires zip: C1180AAX country: Argentina lat: -34.61315 lon: -58.37723 facility: Research Site city: Buenos Aires zip: C1430EGF country: Argentina lat: -34.61315 lon: -58.37723 facility: Research Site city: Caba zip: C1425AGC country: Argentina lat: -34.61315 lon: -58.37723 facility: Research Site city: Ciudad de Buenos Aires zip: C1419AHL country: Argentina lat: -34.61315 lon: -58.37723 facility: Research Site city: Cordoba zip: X5006CBI country: Argentina lat: -31.4135 lon: -64.18105 facility: Research Site city: Corrientes zip: W3400CDS country: Argentina lat: -27.4806 lon: -58.8341 facility: Research Site city: Córdoba zip: X5003DCE country: Argentina lat: -31.4135 lon: -64.18105 facility: Research Site city: Esperanza zip: S3080BQU country: Argentina lat: -31.4488 lon: -60.93173 facility: Research Site city: Florencio Varela zip: 1888 country: Argentina lat: -34.82722 lon: -58.39556 facility: Research Site city: Ganadero Baigorria zip: 2152 country: Argentina facility: Research Site city: Mar del Plata zip: B7600GNY country: Argentina lat: -38.00228 lon: -57.55754 facility: Research Site city: Rosario zip: 2123 country: Argentina lat: -32.94682 lon: -60.63932 facility: Research Site city: San Miguel de Tucuman zip: 4000 country: Argentina lat: -26.82414 lon: -65.2226 facility: Research Site city: San Miguel de Tucuman zip: T4000ICL country: Argentina lat: -26.82414 lon: -65.2226 facility: Research Site city: Santa Fe zip: S3000FWO country: Argentina lat: -31.63333 lon: -60.7 facility: Research Site city: Chermside zip: 4032 country: Australia lat: -27.38472 lon: 153.03062 facility: Research Site city: Geelong zip: 3220 country: Australia lat: -38.14711 lon: 144.36069 facility: Research Site city: Braunau am Inn zip: 5280 country: Austria lat: 48.25628 lon: 13.04343 facility: Research Site city: Graz zip: 8036 country: Austria lat: 47.06667 lon: 15.45 facility: Research Site city: Linz zip: 4020 country: Austria lat: 48.30639 lon: 14.28611 facility: Research Site city: Saint Stefan/Stainz zip: 8511 country: Austria facility: Research Site city: Salzburg zip: 5020 country: Austria lat: 47.79941 lon: 13.04399 facility: Research Site city: St. Pölten zip: 3100 country: Austria lat: 48.2 lon: 15.63333 facility: Research Site city: Wien zip: 1090 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: Wien zip: 1100 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: Wien zip: 1160 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: New Westminster state: British Columbia zip: V3L 3W4 country: Canada lat: 49.20678 lon: -122.91092 facility: Research Site city: North Vancouver state: British Columbia zip: V7M 2H4 country: Canada lat: 49.31636 lon: -123.06934 facility: Research Site city: Vancouver state: British Columbia zip: V6Z 1Y6 country: Canada lat: 49.24966 lon: -123.11934 facility: Research Site city: Winnipeg state: Manitoba zip: R2H 2A6 country: Canada lat: 49.8844 lon: -97.14704 facility: Research Site city: Sydney state: Nova Scotia zip: B1P 1P3 country: Canada lat: 46.13511 lon: -60.1831 facility: Research Site city: Cambridge state: Ontario zip: N1R 6V6 country: Canada lat: 43.3601 lon: -80.31269 facility: Research Site city: London state: Ontario zip: N6A 5A5 country: Canada lat: 42.98339 lon: -81.23304 facility: Research Site city: Newmarket state: Ontario zip: L3Y 2P6 country: Canada lat: 44.05011 lon: -79.46631 facility: Research Site city: North York state: Ontario zip: M6B 3H7 country: Canada lat: 43.76681 lon: -79.4163 facility: Research Site city: Oshawa state: Ontario zip: L1J 2K1 country: Canada lat: 43.90012 lon: -78.84957 facility: Research Site city: Ottawa state: Ontario zip: K1Y 4W7 country: Canada lat: 45.41117 lon: -75.69812 facility: Research Site city: Peterborough state: Ontario zip: K9J 0B2 country: Canada lat: 44.30012 lon: -78.31623 facility: Research Site city: Toronto state: Ontario zip: M6G 1M2 country: Canada lat: 43.70011 lon: -79.4163 facility: Research Site city: Waterloo state: Ontario zip: N2T 0C1 country: Canada lat: 43.4668 lon: -80.51639 facility: Research Site city: Chicoutimi state: Quebec zip: G7H 7K9 country: Canada lat: 48.41963 lon: -71.06369 facility: Research Site city: Greenfield Park state: Quebec zip: J4V 2H1 country: Canada lat: 45.48649 lon: -73.46223 facility: Research Site city: Montreal state: Quebec zip: H3G 1A4 country: Canada lat: 45.50884 lon: -73.58781 facility: Research Site city: Montreal state: Quebec zip: H4J 1C5 country: Canada lat: 45.50884 lon: -73.58781 facility: Research Site city: St Jean sur Richelieu state: Quebec zip: J3A 1J2 country: Canada lat: 45.30713 lon: -73.26259 facility: Research Site city: Trois-Rivières state: Quebec zip: G9A 4P3 country: Canada lat: 46.34515 lon: -72.5477 facility: Research Site city: Antofagasta country: Chile lat: -23.65236 lon: -70.3954 facility: Research Site city: Santiago zip: 7500587 country: Chile lat: -33.45694 lon: -70.64827 facility: Research Site city: Santiago zip: 8330044 country: Chile lat: -33.45694 lon: -70.64827 facility: Research Site city: Temuco zip: 4781156 country: Chile lat: -38.73965 lon: -72.59842 facility: Research Site city: Temuco zip: 4810345 country: Chile lat: -38.73965 lon: -72.59842 facility: Research Site city: Valdivia zip: 5110683 country: Chile lat: -39.81422 lon: -73.24589 facility: Research Site city: Victoria zip: 4720097 country: Chile lat: -38.23291 lon: -72.33292 facility: Research Site city: Beijing zip: 100029 country: China lat: 39.9075 lon: 116.39723 facility: Research Site city: Beijing zip: 100730 country: China lat: 39.9075 lon: 116.39723 facility: Research Site city: Changsha zip: 430033 country: China lat: 28.19874 lon: 112.97087 facility: Research Site city: Chengdu zip: 610041 country: China lat: 30.66667 lon: 104.06667 facility: Research Site city: Hangzhou zip: 310014 country: China lat: 30.29365 lon: 120.16142 facility: Research Site city: Lanzhou zip: 730030 country: China lat: 36.05701 lon: 103.83987 facility: Research Site city: Nanjing zip: 210029 country: China lat: 32.06167 lon: 118.77778 facility: Research Site city: Wuhan zip: 430022 country: China lat: 30.58333 lon: 114.26667 facility: Research Site city: Xian zip: 710061 country: China lat: 34.25833 lon: 108.92861 facility: Research Site city: Barranquilla zip: 80007 country: Colombia lat: 10.96854 lon: -74.78132 facility: Research Site city: Bogotá country: Colombia lat: 4.60971 lon: -74.08175 facility: Research Site city: Cali zip: 760036 country: Colombia lat: 3.43722 lon: -76.5225 facility: Research Site city: Brno zip: 60200 country: Czechia lat: 49.19522 lon: 16.60796 facility: Research Site city: Brno zip: 639 00 country: Czechia lat: 49.19522 lon: 16.60796 facility: Research Site city: Broumov zip: 55001 country: Czechia lat: 50.58566 lon: 16.33181 facility: Research Site city: Ceska Lipa zip: 470 77 country: Czechia lat: 50.68551 lon: 14.53764 facility: Research Site city: Jaromer zip: 551 01 country: Czechia lat: 50.3562 lon: 15.92136 facility: Research Site city: Louny zip: 440 01 country: Czechia lat: 50.35699 lon: 13.79667 facility: Research Site city: Plzen - Bory zip: 305 99 country: Czechia lat: 49.74747 lon: 13.37759 facility: Research Site city: Plzen zip: 31001 country: Czechia lat: 49.74747 lon: 13.37759 facility: Research Site city: Praha 2 zip: 120 00 country: Czechia lat: 50.08804 lon: 14.42076 facility: Research Site city: Prerov zip: 75152 country: Czechia lat: 49.45511 lon: 17.4509 facility: Research Site city: Slany zip: 274 01 country: Czechia lat: 50.23046 lon: 14.08693 facility: Research Site city: Svitavy zip: 568 25 country: Czechia lat: 49.75594 lon: 16.46829 facility: Research Site city: Ustí nad Labem zip: 40011 country: Czechia lat: 50.6607 lon: 14.03227 facility: Research Site city: Zlin zip: 760 01 country: Czechia lat: 49.22645 lon: 17.67065 facility: Research Site city: Helsinki zip: 00290 country: Finland lat: 60.16952 lon: 24.93545 facility: Research Site city: Jyväskylä zip: 40620 country: Finland lat: 62.24147 lon: 25.72088 facility: Research Site city: Tampere zip: 33520 country: Finland lat: 61.49911 lon: 23.78712 facility: Research Site city: Turku zip: 20520 country: Finland lat: 60.45148 lon: 22.26869 facility: Research Site city: Beziers zip: 34500 country: France lat: 43.34122 lon: 3.21402 facility: Research Site city: Bron zip: 69667 country: France lat: 45.73333 lon: 4.91667 facility: Research Site city: Caen Cedex 9 zip: 14033 country: France lat: 49.18585 lon: -0.35912 facility: Research Site city: Creteil zip: 94010 country: France lat: 48.78333 lon: 2.46667 facility: Research Site city: Dijon zip: 21079 country: France lat: 47.31667 lon: 5.01667 facility: Research Site city: La Tronche zip: 38043 country: France lat: 45.20429 lon: 5.73645 facility: Research Site city: Le Coudray zip: 28630 country: France lat: 48.42115 lon: 1.50057 facility: Research Site city: Limoges zip: 87000 country: France lat: 45.83153 lon: 1.25781 facility: Research Site city: Montauban zip: 82017 country: France lat: 44.01667 lon: 1.35 facility: Research Site city: Montpellier Cedex zip: 34295 country: France lat: 43.61092 lon: 3.87723 facility: Research Site city: Nantes cedex 1 zip: 44093 country: France lat: 47.21725 lon: -1.55336 facility: Research Site city: Orleans zip: 45100 country: France lat: 47.90289 lon: 1.90389 facility: Research Site city: Paris zip: 75010 country: France lat: 48.85341 lon: 2.3488 facility: Research Site city: Paris zip: 75015 country: France lat: 48.85341 lon: 2.3488 facility: Research Site city: Poitiers zip: 86021 country: France lat: 46.58333 lon: 0.33333 facility: Research Site city: Reims zip: 51092 country: France lat: 49.25 lon: 4.03333 facility: Research Site city: Rennes Cedex 9 zip: 35033 country: France lat: 48.11198 lon: -1.67429 facility: Research Site city: Toulon zip: 83100 country: France lat: 43.12442 lon: 5.92836 facility: Research Site city: Toulouse zip: 31059 country: France lat: 43.60426 lon: 1.44367 facility: Research Site city: TOURS Cedex 9 zip: 37044 country: France lat: 47.38333 lon: 0.68333 facility: Research Site city: Valenciennes zip: 59300 country: France lat: 50.35 lon: 3.53333 facility: Research Site city: Bad Nauheim zip: 61231 country: Germany lat: 50.36463 lon: 8.73859 facility: Research Site city: Bechhofen zip: 66894 country: Germany lat: 49.35 lon: 7.4 facility: Research Site city: Bernau bei Berlin zip: 16321 country: Germany lat: 52.67982 lon: 13.58708 facility: Research Site city: Chemnitz zip: 9113 country: Germany lat: 50.8357 lon: 12.92922 facility: Research Site city: Coburg zip: 96450 country: Germany lat: 50.25937 lon: 10.96384 facility: Research Site city: Dresden zip: 1307 country: Germany lat: 51.05089 lon: 13.73832 facility: Research Site city: Elsterwerda zip: 04910 country: Germany lat: 51.46043 lon: 13.52001 facility: Research Site city: Frankfurt zip: 60590 country: Germany lat: 50.11552 lon: 8.68417 facility: Research Site city: Freiburg zip: 79106 country: Germany lat: 47.9959 lon: 7.85222 facility: Research Site city: Hagen zip: 58135 country: Germany lat: 51.36081 lon: 7.47168 facility: Research Site city: Hamburg zip: 20246 country: Germany lat: 53.57532 lon: 10.01534 facility: Research Site city: Hamburg zip: 22457 country: Germany lat: 53.57532 lon: 10.01534 facility: Research Site city: Kaiserslautern zip: 67655 country: Germany lat: 49.443 lon: 7.77161 facility: Research Site city: Köln zip: 50733 country: Germany lat: 50.93333 lon: 6.95 facility: Research Site city: Langen zip: 63225 country: Germany lat: 49.98955 lon: 8.66852 facility: Research Site city: Leipzig zip: 04103 country: Germany lat: 51.33962 lon: 12.37129 facility: Research Site city: Leverkusen zip: 51375 country: Germany lat: 51.0303 lon: 6.98432 facility: Research Site city: Mainz zip: 55131 country: Germany lat: 49.98419 lon: 8.2791 facility: Research Site city: Mönchengladbach zip: 41063 country: Germany lat: 51.18539 lon: 6.44172 facility: Research Site city: Papenburg zip: 26871 country: Germany lat: 53.07738 lon: 7.40444 facility: Research Site city: Regensburg zip: 93053 country: Germany lat: 49.01513 lon: 12.10161 facility: Research Site city: Remscheid zip: 42859 country: Germany lat: 51.17983 lon: 7.1925 facility: Research Site city: Rostock zip: 18059 country: Germany lat: 54.0887 lon: 12.14049 facility: Research Site city: Völklingen zip: 66333 country: Germany lat: 49.25162 lon: 6.85873 facility: Research Site city: Wermsdorf zip: 04779 country: Germany lat: 51.28333 lon: 12.95 facility: Research Site city: Witten zip: 58455 country: Germany lat: 51.44362 lon: 7.35258 facility: Research Site city: Athens zip: 11521 country: Greece lat: 37.97945 lon: 23.71622 facility: Research Site city: Athens zip: 11526 country: Greece lat: 37.97945 lon: 23.71622 facility: Research Site city: Athens zip: 11527 country: Greece lat: 37.97945 lon: 23.71622 facility: Research Site city: Athens zip: 12462 country: Greece lat: 37.97945 lon: 23.71622 facility: Research Site city: Athens zip: 14233 country: Greece lat: 37.97945 lon: 23.71622 facility: Research Site city: Athens zip: 15123 country: Greece lat: 37.97945 lon: 23.71622 facility: Research Site city: Dragana zip: 68100 country: Greece facility: Research Site city: Heraklio zip: 71110 country: Greece facility: Research Site city: Thessaloniki zip: 54636 country: Greece lat: 40.64361 lon: 22.93086 facility: Research Site city: Thessaloniki zip: 54642 country: Greece lat: 40.64361 lon: 22.93086 facility: Research Site city: Budapest zip: 1122 country: Hungary lat: 47.49801 lon: 19.03991 facility: Research Site city: Afula zip: 1834111 country: Israel lat: 32.60907 lon: 35.2892 facility: Research Site city: Ashkelon zip: 78278 country: Israel lat: 31.66926 lon: 34.57149 facility: Research Site city: Be'er Ya'akov zip: 70300 country: Israel facility: Research Site city: Beer Sheva zip: 8410101 country: Israel lat: 31.25181 lon: 34.7913 facility: Research Site city: Haifa zip: 3109601 country: Israel lat: 32.81841 lon: 34.9885 facility: Research Site city: Jerusalem zip: 00000 country: Israel lat: 31.76904 lon: 35.21633 facility: Research Site city: Kfar-Saba zip: 4428164 country: Israel lat: 32.175 lon: 34.90694 facility: Research Site city: Nahariya zip: 22100 country: Israel lat: 33.00892 lon: 35.09814 facility: Research Site city: Petah Tikva zip: 49372 country: Israel lat: 32.08707 lon: 34.88747 facility: Research Site city: Tiberias zip: 15208 country: Israel lat: 32.79221 lon: 35.53124 facility: Research Site city: Acquaviva delle Fonti zip: 70021 country: Italy lat: 40.89704 lon: 16.8433 facility: Research Site city: Bari zip: 70124 country: Italy lat: 41.11148 lon: 16.8554 facility: Research Site city: Bergamo zip: 24127 country: Italy lat: 45.69601 lon: 9.66721 facility: Research Site city: Brescia zip: 25100 country: Italy lat: 45.53558 lon: 10.21472 facility: Research Site city: Catanzaro zip: 88100 country: Italy lat: 38.88247 lon: 16.60086 facility: Research Site city: Cona zip: 44124 country: Italy lat: 44.80583 lon: 11.7069 facility: Research Site city: Cortona zip: 52044 country: Italy lat: 43.27467 lon: 11.98533 facility: Research Site city: Firenze zip: 50134 country: Italy lat: 43.77925 lon: 11.24626 facility: Research Site city: Milan zip: 20138 country: Italy lat: 45.46427 lon: 9.18951 facility: Research Site city: Novara zip: 28100 country: Italy lat: 45.44694 lon: 8.62118 facility: Research Site city: Pavia zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 facility: Research Site city: San Giovanni Rotondo zip: 71013 country: Italy lat: 41.70643 lon: 15.7277 facility: Research Site city: Fujisawa-shi zip: 251-8550 country: Japan lat: 35.34926 lon: 139.47666 facility: Research Site city: Fukutsu-shi zip: 811-3298 country: Japan lat: 33.783 lon: 130.49114 facility: Research Site city: Hakusan-shi zip: 924-8588 country: Japan facility: Research Site city: Himeji zip: 670-8560 country: Japan lat: 34.81667 lon: 134.7 facility: Research Site city: Iwakuni-shi zip: 740-8510 country: Japan lat: 34.16297 lon: 132.22 facility: Research Site city: Kawaguchi zip: 333-0842 country: Japan lat: 35.80521 lon: 139.71072 facility: Research Site city: Kobe-shi zip: 654-0155 country: Japan lat: 34.6913 lon: 135.183 facility: Research Site city: Matsumoto-shi zip: 390-8621 country: Japan lat: 36.23333 lon: 137.96667 facility: Research Site city: Moriyama-shi zip: 524-8524 country: Japan lat: 35.06667 lon: 135.98333 facility: Research Site city: Oita-shi zip: 870-8511 country: Japan lat: 33.23333 lon: 131.6 facility: Research Site city: Osaka-shi zip: 540-0006 country: Japan lat: 34.69374 lon: 135.50218 facility: Research Site city: Sagamihara-shi zip: 252-5188 country: Japan lat: 35.54899 lon: 139.26064 facility: Research Site city: Saitama shi zip: 336 8522 country: Japan lat: 35.90807 lon: 139.65657 facility: Research Site city: Sakai-shi zip: 599-8247 country: Japan lat: 34.58333 lon: 135.46667 facility: Research Site city: Sakata City zip: 998-8501 country: Japan lat: 38.91667 lon: 139.855 facility: Research Site city: Toshima-ku zip: 171-0014 country: Japan facility: Research Site city: Ueda-shi zip: 386-8610 country: Japan lat: 36.40265 lon: 138.28161 facility: Research Site city: Uji-shi zip: 611-0041 country: Japan lat: 34.89044 lon: 135.80325 facility: Research Site city: Uwajima-shi zip: 798-8510 country: Japan lat: 33.22375 lon: 132.56001 facility: Research Site city: Yokohama-shi zip: 221-0855 country: Japan lat: 35.43333 lon: 139.65 facility: Research Site city: Busan zip: 49241 country: Korea, Republic of lat: 35.10278 lon: 129.04028 facility: Research Site city: Seongnam-si zip: 13620 country: Korea, Republic of lat: 37.43861 lon: 127.13778 facility: Research Site city: Seoul zip: 03722 country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Research Site city: Wonju-si zip: 26426 country: Korea, Republic of facility: Research Site city: Kajang zip: 43000 country: Malaysia lat: 2.99424 lon: 101.78875 facility: Research Site city: Kota Kinabalu zip: 88300 country: Malaysia lat: 5.9749 lon: 116.0724 facility: Research Site city: Kota Samarahan zip: 94300 country: Malaysia facility: Research Site city: Kuala Lumpur zip: 50400 country: Malaysia lat: 3.1412 lon: 101.68653 facility: Research Site city: Kuala Terengganu zip: 20400 country: Malaysia lat: 5.3302 lon: 103.1408 facility: Research Site city: Kuantan zip: 25200 country: Malaysia lat: 3.8077 lon: 103.326 facility: Research Site city: Sungai Buloh zip: 47000 country: Malaysia lat: 3.2 lon: 101.58333 facility: Research Site city: Aguascalientes zip: 20230 country: Mexico lat: 21.88234 lon: -102.28259 facility: Research Site city: Cuauhtémoc zip: 06700 country: Mexico lat: 19.44506 lon: -99.14612 facility: Research Site city: Culiacán zip: 80200 country: Mexico lat: 24.79032 lon: -107.38782 facility: Research Site city: Guadalajara zip: 44670 country: Mexico lat: 20.66682 lon: -103.39182 facility: Research Site city: Mazatlán zip: 82110 country: Mexico lat: 23.2329 lon: -106.4062 facility: Research Site city: Metepec zip: 52170 country: Mexico lat: 19.25934 lon: -99.60175 facility: Research Site city: Mexico City zip: 03310 country: Mexico lat: 19.42847 lon: -99.12766 facility: Research Site city: Mexico City zip: 07300 country: Mexico lat: 19.42847 lon: -99.12766 facility: Research Site city: Mexico zip: 14080 country: Mexico lat: 19.42847 lon: -99.12766 facility: Research Site city: Monterey zip: 64060 country: Mexico facility: Research Site city: Morelia zip: 58260 country: Mexico lat: 19.70078 lon: -101.18443 facility: Research Site city: México zip: 11650 country: Mexico lat: 19.42847 lon: -99.12766 facility: Research Site city: Querétaro zip: 76000 country: Mexico facility: Research Site city: San Luis Potosí zip: 78250 country: Mexico lat: 22.14982 lon: -100.97916 facility: Research Site city: Tijuana zip: 22014 country: Mexico lat: 32.5027 lon: -117.00371 facility: Research Site city: Veracruz zip: 91910 country: Mexico lat: 19.18095 lon: -96.1429 facility: Research Site city: Xalapa zip: 91193 country: Mexico lat: 19.53124 lon: -96.91589 facility: Research Site city: Arnhem zip: 6815 AD country: Netherlands lat: 51.98 lon: 5.91111 facility: Research Site city: Emmen zip: 7824 AA country: Netherlands lat: 52.77917 lon: 6.90694 facility: Research Site city: Goes zip: 4462 RA country: Netherlands lat: 51.50417 lon: 3.88889 facility: Research Site city: Groningen zip: 9728 NT country: Netherlands lat: 53.21917 lon: 6.56667 facility: Research Site city: Hardenberg zip: 7772 SE country: Netherlands lat: 52.57583 lon: 6.61944 facility: Research Site city: Bellavista zip: CALLAO 2 country: Peru lat: -7.05614 lon: -76.5911 facility: Research Site city: Lima zip: 15024 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Lima zip: 15046 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Lima zip: 15072 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Lima zip: 15088 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Lima zip: 15131 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Lima zip: L18 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Lima zip: LIMA 11 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Lima zip: LIMA 27 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Lima zip: LIMA 41 country: Peru lat: -12.04318 lon: -77.02824 facility: Research Site city: Piura zip: 20001 country: Peru lat: -5.19449 lon: -80.63282 facility: Research Site city: Angeles City zip: 2009 country: Philippines lat: 15.15 lon: 120.58333 facility: Research Site city: Davao City zip: 8000 country: Philippines lat: 7.07306 lon: 125.61278 facility: Research Site city: Davao City zip: PH-8000 country: Philippines lat: 7.07306 lon: 125.61278 facility: Research Site city: Iloilo City zip: 5000 country: Philippines lat: 10.69694 lon: 122.56444 facility: Research Site city: Las Pinas City zip: PH-1704 country: Philippines facility: Research Site city: Mabalacat zip: 2023 country: Philippines lat: 15.22303 lon: 120.57117 facility: Research Site city: Manadaluyong City zip: 1552 country: Philippines facility: Research Site city: Manila zip: 1008 country: Philippines lat: 14.6042 lon: 120.9822 facility: Research Site city: Marikina zip: 1800 country: Philippines facility: Research Site city: Pasig City zip: 1605 country: Philippines lat: 14.58691 lon: 121.0614 facility: Research Site city: Quezon City zip: 1101 country: Philippines lat: 14.6488 lon: 121.0509 facility: Research Site city: Quezon City zip: 1112 country: Philippines lat: 14.6488 lon: 121.0509 facility: Research Site city: Taguig City zip: 1634 country: Philippines facility: Research Site city: West San Juan City zip: 1502 country: Philippines facility: Research Site city: Biała Podlaska zip: 21-500 country: Poland lat: 52.03238 lon: 23.11652 facility: Research Site city: Białystok zip: 15-481 country: Poland lat: 53.13333 lon: 23.16433 facility: Research Site city: Bielsko-Biała zip: 43-316 country: Poland lat: 49.82245 lon: 19.04686 facility: Research Site city: Bydgoszcz zip: 85-605 country: Poland lat: 53.1235 lon: 18.00762 facility: Research Site city: Bydgoszcz zip: 85-794 country: Poland lat: 53.1235 lon: 18.00762 facility: Research Site city: Chrzanów zip: 32-500 country: Poland lat: 50.13546 lon: 19.40203 facility: Research Site city: Gdynia zip: 81-157 country: Poland lat: 54.51889 lon: 18.53188 facility: Research Site city: Kazimierza Wielka zip: 28-500 country: Poland lat: 50.26564 lon: 20.49358 facility: Research Site city: Kraków zip: 30-082 country: Poland lat: 50.06143 lon: 19.93658 facility: Research Site city: Kraków zip: 30-688 country: Poland lat: 50.06143 lon: 19.93658 facility: Research Site city: Kraków zip: 31-513 country: Poland lat: 50.06143 lon: 19.93658 facility: Research Site city: Kędzierzyn-Koźle zip: 47-200 country: Poland lat: 50.34984 lon: 18.22606 facility: Research Site city: Lublin zip: 20-044 country: Poland lat: 51.25 lon: 22.56667 facility: Research Site city: Lublin zip: 20-857 country: Poland lat: 51.25 lon: 22.56667 facility: Research Site city: Olsztyn zip: 10-010 country: Poland lat: 53.77995 lon: 20.49416 facility: Research Site city: Piekary Śląskie zip: 41-940 country: Poland lat: 50.38017 lon: 18.92653 facility: Research Site city: Poznań zip: 61- 848 country: Poland lat: 52.40692 lon: 16.92993 facility: Research Site city: Rzeszow zip: 35-055 country: Poland lat: 50.04132 lon: 21.99901 facility: Research Site city: Rzeszów zip: 35-205 country: Poland lat: 50.04132 lon: 21.99901 facility: Research Site city: Szczecin zip: 71-526 country: Poland lat: 53.42894 lon: 14.55302 facility: Research Site city: Tarnów zip: 33-100 country: Poland lat: 50.01381 lon: 20.98698 facility: Research Site city: Toruń zip: 87-100 country: Poland lat: 53.01375 lon: 18.59814 facility: Research Site city: Tychy zip: 43-100 country: Poland lat: 50.13717 lon: 18.96641 facility: Research Site city: Warszawa zip: 00-416 country: Poland lat: 52.22977 lon: 21.01178 facility: Research Site city: Warszawa zip: 04-501 country: Poland lat: 52.22977 lon: 21.01178 facility: Research Site city: Zabrze zip: 41-800 country: Poland lat: 50.32492 lon: 18.78576 facility: Research Site city: Łódź zip: 90-549 country: Poland lat: 51.75 lon: 19.46667 facility: Research Site city: Łódź zip: 91-053 country: Poland lat: 51.75 lon: 19.46667 facility: Research Site city: Łódź zip: 93-513 country: Poland lat: 51.75 lon: 19.46667 facility: Research Site city: Łódź zip: 94-046 country: Poland lat: 51.75 lon: 19.46667 facility: Research Site city: Bucharest zip: 014461 country: Romania lat: 44.43225 lon: 26.10626 facility: Research Site city: Bucharest zip: 040883 country: Romania lat: 44.43225 lon: 26.10626 facility: Research Site city: Bucuresti zip: 022328 country: Romania lat: 44.42802 lon: 26.09665 facility: Research Site city: Cluj-Napoca zip: 400437 country: Romania lat: 46.76667 lon: 23.6 facility: Research Site city: Iasi zip: 700503 country: Romania lat: 47.16667 lon: 27.6 facility: Research Site city: Targu Mures zip: 540099 country: Romania lat: 46.54245 lon: 24.55747 facility: Research Site city: Targu Mures zip: 540136 country: Romania lat: 46.54245 lon: 24.55747 facility: Research Site city: Timisoara zip: 300595 country: Romania lat: 45.75372 lon: 21.22571 facility: Research Site city: Timișoara zip: 300310 country: Romania lat: 45.75372 lon: 21.22571 facility: Research Site city: Bratislava zip: 831 01 country: Slovakia lat: 48.14816 lon: 17.10674 facility: Research Site city: Brezno zip: 977 01 country: Slovakia lat: 48.80431 lon: 19.63631 facility: Research Site city: Kosice zip: 04022 country: Slovakia lat: 48.71395 lon: 21.25808 facility: Research Site city: Martin zip: 036 01 country: Slovakia lat: 49.06651 lon: 18.92399 facility: Research Site city: Myjava zip: 90701 country: Slovakia lat: 48.75876 lon: 17.56866 facility: Research Site city: Nitra zip: 949 01 country: Slovakia lat: 48.30763 lon: 18.08453 facility: Research Site city: Nove Zamky zip: 940 01 country: Slovakia lat: 47.98544 lon: 18.16195 facility: Research Site city: Považská Bystrica zip: 017 01 country: Slovakia lat: 49.12153 lon: 18.42169 facility: Research Site city: Presov zip: 080 01 country: Slovakia lat: 48.99839 lon: 21.23393 facility: Research Site city: Prešov zip: 080 01 country: Slovakia lat: 48.99839 lon: 21.23393 facility: Research Site city: Rimavska Sobota zip: 979 01 country: Slovakia lat: 48.38284 lon: 20.02239 facility: Research Site city: Svidník zip: 08901 country: Slovakia lat: 49.30819 lon: 21.5703 facility: Research Site city: A Coruña zip: 15006 country: Spain lat: 43.37135 lon: -8.396 facility: Research Site city: Barcelona zip: 08025 country: Spain lat: 41.38879 lon: 2.15899 facility: Research Site city: Barcelona zip: 08035 country: Spain lat: 41.38879 lon: 2.15899 facility: Research Site city: Barcelona zip: 08036 country: Spain lat: 41.38879 lon: 2.15899 facility: Research Site city: Lugo zip: 27004 country: Spain lat: 43.00992 lon: -7.55602 facility: Research Site city: Madrid zip: 28007 country: Spain lat: 40.4165 lon: -3.70256 facility: Research Site city: Madrid zip: 28027 country: Spain lat: 40.4165 lon: -3.70256 facility: Research Site city: Majadahonda zip: 28222 country: Spain lat: 40.47353 lon: -3.87182 facility: Research Site city: Sevilla zip: 41009 country: Spain lat: 37.38283 lon: -5.97317 facility: Research Site city: Sevilla zip: 41014 country: Spain lat: 37.38283 lon: -5.97317 facility: Research Site city: Alingsås zip: 441 83 country: Sweden lat: 57.93033 lon: 12.53345 facility: Research Site city: Göteborg zip: 413 46 country: Sweden lat: 57.70716 lon: 11.96679 facility: Research Site city: Helsingborg zip: 252 23 country: Sweden lat: 56.04673 lon: 12.69437 facility: Research Site city: Jönköping zip: 551 85 country: Sweden lat: 57.78145 lon: 14.15618 facility: Research Site city: Karlstad zip: 651 85 country: Sweden lat: 59.3793 lon: 13.50357 facility: Research Site city: Lund zip: 22242 country: Sweden lat: 55.70584 lon: 13.19321 facility: Research Site city: Stockholm zip: 118 83 country: Sweden lat: 59.33258 lon: 18.0649 facility: Research Site city: Stockholm zip: 171 64 country: Sweden lat: 59.33258 lon: 18.0649 facility: Research Site city: Uppsala zip: 75185 country: Sweden lat: 59.85882 lon: 17.63889 facility: Research Site city: Västerås zip: 723 35 country: Sweden lat: 59.61617 lon: 16.55276 facility: Research Site city: Changhua zip: 500 country: Taiwan lat: 24.07327 lon: 120.56276 facility: Research Site city: Kaohsiung zip: 80756 country: Taiwan lat: 22.61626 lon: 120.31333 facility: Research Site city: Kaohsiung zip: 81362 country: Taiwan lat: 22.61626 lon: 120.31333 facility: Research Site city: New Taipei City zip: 25160 country: Taiwan lat: 25.01111 lon: 121.44583 facility: Research Site city: New Taipei zip: 220 country: Taiwan lat: 25.01111 lon: 121.44583 facility: Research Site city: New Taipei zip: 231 country: Taiwan lat: 25.01111 lon: 121.44583 facility: Research Site city: Taichung zip: 40447 country: Taiwan lat: 24.1469 lon: 120.6839 facility: Research Site city: Taichung zip: 433 country: Taiwan lat: 24.1469 lon: 120.6839 facility: Research Site city: Taipei City zip: 110 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 0116 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 10002 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 10449 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 11101 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 11217 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: TAIWAN country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taoyuan zip: 333 country: Taiwan lat: 24.95233 lon: 121.20193 facility: Research Site city: Yilan zip: 260 country: Taiwan lat: 24.757 lon: 121.753 facility: Research Site city: Yung Kang City zip: 71044 country: Taiwan facility: Research Site city: Bangkok zip: 10330 country: Thailand lat: 13.75398 lon: 100.50144 facility: Research Site city: Bangkok zip: 10400 country: Thailand lat: 13.75398 lon: 100.50144 facility: Research Site city: Chiang Mai zip: 50200 country: Thailand lat: 18.79038 lon: 98.98468 facility: Research Site city: Hat Yai zip: 90110 country: Thailand lat: 7.00836 lon: 100.47668 facility: Research Site city: Khon Kaen zip: 40002 country: Thailand lat: 16.44671 lon: 102.833 facility: Research Site city: Naimuang zip: 30000 country: Thailand facility: Research Site city: Pathumthani zip: 12120 country: Thailand lat: 14.01346 lon: 100.53049 facility: Research Site city: Adana zip: 01060 country: Turkey lat: 37.00167 lon: 35.32889 facility: Research Site city: Ankara zip: 06 country: Turkey lat: 39.91987 lon: 32.85427 facility: Research Site city: Antalya zip: 07059 country: Turkey lat: 36.90812 lon: 30.69556 facility: Research Site city: Antalya zip: 07100 country: Turkey lat: 36.90812 lon: 30.69556 facility: Research Site city: Dinar zip: 03400 country: Turkey lat: 38.065 lon: 30.16557 facility: Research Site city: Eskisehir zip: 26480 country: Turkey lat: 39.77667 lon: 30.52056 facility: Research Site city: Istanbul zip: 34668 country: Turkey lat: 41.01384 lon: 28.94966 facility: Research Site city: Izmir zip: 35340 country: Turkey lat: 38.41273 lon: 27.13838 facility: Research Site city: Kocaeli zip: 41380 country: Turkey lat: 39.62497 lon: 27.51145 facility: Research Site city: Kütahya zip: 43100 country: Turkey lat: 39.42417 lon: 29.98333 facility: Research Site city: Merkez zip: 78200 country: Turkey facility: Research Site city: Mugla zip: 48000 country: Turkey lat: 37.21807 lon: 28.3665 facility: Research Site city: Sivas zip: 58140 country: Turkey lat: 39.74833 lon: 37.01611 facility: Research Site city: Airdrie zip: ML6 0JS country: United Kingdom lat: 55.86602 lon: -3.98025 facility: Research Site city: Barnet zip: EN5 3DJ country: United Kingdom lat: 51.65 lon: -0.2 facility: Research Site city: Cambridge zip: CB2 0AY country: United Kingdom lat: 52.2 lon: 0.11667 facility: Research Site city: Chertsey zip: KT16 0PZ country: United Kingdom lat: 51.38812 lon: -0.50782 facility: Research Site city: Clydebank zip: G81 4DY country: United Kingdom lat: 55.90137 lon: -4.4057 facility: Research Site city: Exeter zip: EX2 5DW country: United Kingdom lat: 50.7236 lon: -3.52751 facility: Research Site city: Harefield zip: UB9 6JH country: United Kingdom lat: 51.60333 lon: -0.48546 facility: Research Site city: Hastings zip: TN37 7RD country: United Kingdom lat: 50.85519 lon: 0.57292 facility: Research Site city: High Wycombe zip: HP11 2TT country: United Kingdom lat: 51.62907 lon: -0.74934 facility: Research Site city: King's Lynn zip: PE30 4ET country: United Kingdom lat: 52.75172 lon: 0.39516 facility: Research Site city: Lincoln zip: LN2 5QY country: United Kingdom lat: 53.22683 lon: -0.53792 facility: Research Site city: London zip: EC1A 7BE country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Research Site city: London zip: SE5 9RS country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Research Site city: Middlesborough zip: TS4 3BW country: United Kingdom lat: 54.57623 lon: -1.23483 facility: Research Site city: Portsmouth zip: PO6 3LY country: United Kingdom lat: 50.79899 lon: -1.09125 facility: Research Site city: Sheffield zip: S5 7AU country: United Kingdom lat: 53.38297 lon: -1.4659 facility: Research Site city: Sunderland zip: SR4 7TP country: United Kingdom lat: 54.90465 lon: -1.38222 facility: Research Site city: Wakefield zip: WF1 4DG country: United Kingdom lat: 53.68331 lon: -1.49768 facility: Research Site city: Da Nang zip: 550000 country: Vietnam lat: 16.06778 lon: 108.22083 facility: Research Site city: Hai Phong zip: 180000 country: Vietnam lat: 20.86481 lon: 106.68345 facility: Research Site city: Hanoi zip: 100000 country: Vietnam lat: 21.0245 lon: 105.84117 facility: Research Site city: Ho Chi Minh zip: 700000 country: Vietnam lat: 10.82302 lon: 106.62965 facility: Research Site city: Hochiminh city zip: 700000 country: Vietnam lat: 10.82302 lon: 106.62965 hasResults: False
<\|newrecord\|> nctId: NCT06307639 id: MYMSwifee briefTitle: Seminal Levels of PGK2 and ACRV1 as Predictors of Micro-TESE Results in NOA overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-10-01 date: 2026-04-01 date: 2024-03-13 date: 2024-03-13 name: Assiut University class: OTHER briefSummary: * Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).
* Correlate seminal levels of PGK2 and ACRV1 with sperm retrieval results and histopathology analysis of testicular biopsy samples. conditions: Male Infertility Due to Azoospermia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 64 type: ESTIMATED name: Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE). measure: Know more about the functional role of PGK2 and ACRV1 in the process of spermatogenesis. measure: Detect if PGK2 and/or AVRV1 level can used as predictor for spermatogenesis in infertile men with non-obstructive azoospermia undergoing Testicular Sperm Extraction. sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307626 id: ARGX-113-2309 id: 2023-509198-22-00 type: CTIS briefTitle: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. overallStatus: RECRUITING date: 2024-03-28 date: 2026-02 date: 2027-10 date: 2024-03-13 date: 2024-04-04 name: argenx class: INDUSTRY briefSummary: This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC.
After an up to 28-day screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively. Study drug will be administered subcutaneously during the 24-week double-blinded treatment period (DBTP). At the end of the DBTP (week 24), proptosis responders will enter a follow-up observational period (52 weeks) to assess the safety, tolerability, and durability of efgartigimod PH20 SC treatment while off therapy. Proptosis nonresponders and participants who have proptosis relapse during the 52-week follow-up observational period will receive open-label treatment with efgartigimod PH20 SC for up to 24 weeks. conditions: Thyroid Eye Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 108 type: ESTIMATED name: Efgartigimod PH20 SC name: Placebo PH20 SC measure: Percentage of participants who were proptosis responders measure: Change in proptosis measurement in the study eye from baseline measure: Change in the total Graves' Orbitopathy Quality of Life (GO-QoL) score from baseline measure: Percentage of participants with a resolution of diplopia (responders) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Advanced Research status: RECRUITING city: Boynton Beach state: Florida zip: 33437 country: United States name: Sirtaz S. Sibia, MD role: CONTACT phone: 857-350-4834 email: clinicaltrials@argenx.com lat: 26.52535 lon: -80.06643 hasResults: False
<\|newrecord\|> nctId: NCT06307613 id: ARGX-113-2301 id: 2023-509197-35-00 type: CTIS briefTitle: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease overallStatus: RECRUITING date: 2024-03-27 date: 2026-02 date: 2027-10 date: 2024-03-13 date: 2024-04-04 name: argenx class: INDUSTRY briefSummary: This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC.
After an up to 28-day screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively. Study drug will be administered subcutaneously during the 24-week double-blinded treatment period (DBTP). At the end of the DBTP (week 24), proptosis responders will enter a follow-up observational period (52 weeks) to assess the safety, tolerability, and durability of efgartigimod PH20 SC treatment while off therapy. Proptosis nonresponders and participants who have proptosis relapse during the 52-week follow-up observational period will receive open-label treatment with efgartigimod PH20 SC for up to 24 weeks. conditions: Thyroid Eye Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 108 type: ESTIMATED name: Efgartigimod PH20 SC name: Placebo PH20 SC measure: Percentage of participants who were proptosis responders measure: Change in proptosis measurement in the study eye from baseline measure: Change in the total Graves' Orbitopathy Quality of Life (GO-QoL) score from baseline measure: Percentage of participants with a resolution of diplopia (responders) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Advanced Clinical Research status: RECRUITING city: Coral Springs state: Florida zip: 33067 country: United States name: Shailesh Gupta, MD role: CONTACT phone: 857-350-4834 email: clinicaltrials@argenx.com lat: 26.27119 lon: -80.2706 hasResults: False
<\|newrecord\|> nctId: NCT06307600 id: BHCT-RD06-03 briefTitle: The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-03-15 date: 2027-04-01 date: 2024-03-13 date: 2024-03-13 name: Anhui Provincial Hospital class: OTHER_GOV briefSummary: This study is designed to explore the safety and efficacy for patients with relapsed and/or refractory B-cell lymphoblastic leukemia. conditions: B Lymphoblastic Leukemia/Lymphoma studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 9 type: ESTIMATED name: RD06-03 cell injection measure: Dose-limiting toxicity sex: ALL minimumAge: 3 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Anhui Provincial Hospital city: Hefei state: Anhui zip: 230036 country: China lat: 31.86389 lon: 117.28083 hasResults: False
<\|newrecord\|> nctId: NCT06307587 id: 2023/2355 briefTitle: Vastus Intermedius Dry Needling for Knee Stiffness Resulted From Surgically Managed Femoral Fractures With Open Reduction & Internal Fixation. overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-03-01 date: 2027-03-12 date: 2024-03-13 date: 2024-03-13 name: Al-Razi Hospital class: OTHER_GOV briefSummary: Orthopedic traumatic injuries are considered a major health epidemic, challenged by high morbidity, mortality, and socioeconomic burden. The management of traumatic orthopedic injuries is challenging and complex, with high resources utilization. Particularly, the prevalence of femoral fractures in Kuwait is 8.8%, being one of the most prevalent injuries. Open reduction and internal fixation (ORIF) is a common surgical procedure for the management of femoral fractures demonstrating successful outcome for allowing minimally invasive percutaneous plate osteosynthesis, early union of 93% to 100%, and low infection rate of only 0% to 2%. Yet, one of the major complications post ORIF is knee stiffness and reduced function, which brings many inconveniences to patients' daily lives, lead to disability, and could seriously threaten the functional activities of patients. The incidence of knee stiffness requiring surgical intervention is 14.5%. Particularly, the potential loss of knee flexion is 30 to 40 degrees, 13% of the patients failed to reach 90 degrees of knee flexion, and only 48% of patients reached \>120 degrees of flexion. Ultimately, knee stiffness in flexion forms a major issue in distal femoral fractures. Various reasons could explain such complication including intrinsic adhesions, fibrosis and shortening of the vastus intermedius muscle.
There are various surgical procedures which could be used to manage knee stiffness. However, there is no consensus regarding the ideal approach and strategy with many postoperative complications including deep sepsis, quadricep tendon rupture, skin dehiscence and infection, delayed wound healing, patella fracture, lateral femoral condyle fracture and extension lag. In contrast, dry needling (DN) is a minimal invasive intervention for the management of musculoskeletal dysfunction, and it could be used to reduce the adhesion and fibrosis between the vastus intermedius and the femoral bone. However, there is limited research investigating the effect of DN on the vastus intermedius muscle after ORIF of the femoral fractures. The effectiveness of DN was explored for the management of various musculoskeletal conditions, and a systematic review addressing DN in the lower quarter concluded that DN is an effective procedure (Morihisa et a,., 2016). In ACL reconstruction, DN for the vastus medialis improved ROM at short-term and improved function at both short and long term. DN has been proposed as a useful addition to the rehabilitation of ACL reconstructed in reducing pain intensity, increasing knee flexion range, and modifying the mechanical properties of the quadriceps muscle during the late-stage of rehabilitation. DN has also altered the passive mechanical properties of the quadriceps muscle where decrement and resistance of the vastus medialis were significantly reduced. It is hypothesized that releasing the adhesions and fibrosis of the vastus intermedius could play an important role in managing knee stiffness post ORIF of the distal femur fractures. Therefore, the aim of this project is to identify the incidence rate and risk factors of knee stiffness resulted from surgically managed femoral fractures with open reduction and internal fixation in Kuwait, and to investigate the effect of DN on the vastus intermedius muscle in improving knee joint range of motion and function after ORIF of the distal femur using single blind randomized controlled trial (RCT). conditions: Femur Fracture studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 44 type: ESTIMATED name: dry needling measure: knee flexion range of motion sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307574 id: STUDY00002804 briefTitle: bpMedManage: Digital Technology to Support Adherence to Hypertension Medications overallStatus: RECRUITING date: 2024-02-29 date: 2025-05 date: 2025-12 date: 2024-03-13 date: 2024-04-01 name: University of Arizona class: OTHER name: University of Illinois at Urbana-Champaign briefSummary: The purpose of the bpMedManage study is to rigorously test the efficacy of a smartphone technology to help improve high blood pressure medication adherence among older adults with mild cognitive impairment (MCI) in a 16-week randomized controlled trial. A total of 100 older adults will be recruited. There will be two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on an education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes on primary and secondary measures will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention. conditions: Aging conditions: Mild Cognitive Impairment conditions: Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be screened and randomly assigned to either the bpMedManage-S or bpMedManage-P group primaryPurpose: OTHER masking: SINGLE maskingDescription: All primary and secondary outcome assessments following the intervention, Week 4, are blinded. One of the supplementary outcome measures following the intervention at Week 12, requires the assessor to know the group assignment. This outcome pertains to their experience in the intervention. The follow-up outcome assessments at Week 12 will be administered by an unblinded assessor. whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: bpMedManage measure: Change in medication adherence measured by the Medication Event Monitoring System (MEMS® Cap) measure: Change in self-reported medication adherence measured by the Medication Adherence Report Scale-5 (MARS-5© Professor Rob Horne) measure: Change in Systolic and/or Diastolic blood pressure, as measured by taking blood pressure readings measure: Change in hypertension knowledge measured by the Hypertension Knowledge-Level Scale measure: System Usability measured by the System Usability Scale measure: Opinion Interview sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Arizona status: RECRUITING city: Tucson state: Arizona zip: 85721 country: United States name: Kathleen Insel, PhD role: CONTACT phone: 520-626-6220 email: insel@arizona.edu lat: 32.22174 lon: -110.92648 facility: University of Illinois, Urbana-Champaign status: NOT_YET_RECRUITING city: Champaign state: Illinois zip: 61820 country: United States name: Raksha Mudar, PhD role: CONTACT phone: 217-333-4718 email: raksha@illinois.edu lat: 40.11642 lon: -88.24338 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2024-02-21 uploadDate: 2024-02-21T16:53 filename: Prot_000.pdf size: 560648 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-11-04 uploadDate: 2024-03-08T14:33 filename: ICF_001.pdf size: 563829 hasResults: False
<\|newrecord\|> nctId: NCT06307561 id: GGurzoglu briefTitle: The Effect of Dystonia Severity on Participation in Daily Living Activities and Caregivers in Children of Cerebral Palsy With Secondary Dystonia overallStatus: COMPLETED date: 2021-01-01 date: 2024-01-01 date: 2024-01-01 date: 2024-03-13 date: 2024-03-13 name: Acıbadem Atunizade Hospital class: OTHER briefSummary: Dystonia is the most common movement disorder in the pediatric population after spasticity. It can affect normal motor development and cause significant motor retardation. The presence of dystonia may affect motor function, pain, and ease of care in CP. Additionally, it can cause serious difficulties in daily living activities and social participation and long-term joint deformity. The increase in the severity of dystonia in CP children with secondary dystonia may affect the quality of life, activity and participation of the children, as well as the caregiver. The importance of caregivers is an undeniable fact, especially in these patient groups. This study aims to investigate the burden of dystonia severity on the participation in daily living activities and caregivers of children with CP with secondary dystonia. conditions: Secondary Dystonia conditions: Cerebral Palsy, Mixed studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 20 type: ACTUAL measure: The Barry-Albright Dystonia Scale (BADS) measure: The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD) measure: The Care and Comfort Hypertonicity Questionnaire (CCHQ) sex: ALL minimumAge: 3 Years maximumAge: 15 Years stdAges: CHILD facility: Acıbadem Altunizade Hospital city: Istanbul state: Altunizade zip: 34662 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
<\|newrecord\|> nctId: NCT06307548 id: I-3670923 id: NCI-2024-01256 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: I-3670923 type: OTHER domain: Roswell Park Cancer Institute id: UL1TR001412 type: NIH link: https://reporter.nih.gov/quickSearch/UL1TR001412 briefTitle: Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2027-06-01 date: 2027-06-01 date: 2024-03-13 date: 2024-04-24 name: Roswell Park Cancer Institute class: OTHER name: National Center for Advancing Translational Sciences (NCATS) briefSummary: This phase I/II trial studies the side effects and how well fluorescence image guided surgery followed by intraoperative photodynamic therapy for improving local tumor control in patients with colorectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has come back after a period of improvement (recurrent). Fluorescence image guided surgery uses a drug named aminolevulinic acid hydrochloride. Aminolevulinic acid hydrochloride is a photosensitizing agent, meaning that is activated by light and, is converted to another drug in cancer cells more than in normal cells. The converted drug emits fluorescence red light when activated with low power blue light. It is used to assist the surgeon to see cancer cells and small cancerous tissue that may have been missed during routine surgery. In addition to emitting fluorescence light, the converted drug in the cancer cells and tissue can be activated with red laser light to kill cancer cells. This procedure is called photodynamic therapy (PDT). Performing fluorescence image guided surgery followed by intraoperative photodynamic therapy after the surgical removal of the colorectal tumor before the surgical site will be closed may be effective and improve outcomes in patients with locally advanced or recurrent colorectal cancer. conditions: Locally Advanced Colorectal Carcinoma conditions: Recurrent Colorectal Carcinoma conditions: Stage III Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 21 type: ESTIMATED name: Aminolevulinic Acid name: Biospecimen Collection name: Computed Tomography name: Fluorescence-Guided Surgery name: Magnetic Resonance Imaging name: Photodynamic Therapy name: Surgical Procedure measure: Accuracy of the fluorescence imaging (Phase I) measure: Incidence of adverse events (Phase I) measure: Evidence of disease (Phase II) measure: Changes in carcinoembryonic antigen (CEA) and circulating tumor deoxyribonucleic acid (ctDNA) (Phase II) measure: Changes in CEA and ctDNA (Phase I) measure: Rate of recurrence (Phase I) measure: Rate of local recurrence (Phase II) measure: Disease free survival (Phase II) measure: Correlation between disease free survival and changes in levels of CEA (Phase II) measure: Correlation between disease free survival and changes in levels of ctDNA (Phase II) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Roswell Park Cancer Institute city: Buffalo state: New York zip: 14263 country: United States name: Anthony S. Dakwar role: CONTACT phone: 716-845-5807 email: Anthony.Dakwar@RoswellPark.org name: Anthony S. Dakwar role: PRINCIPAL_INVESTIGATOR lat: 42.88645 lon: -78.87837 hasResults: False
<\|newrecord\|> nctId: NCT06307535 id: 23-376 briefTitle: A Study of Meaning-Centered Psychotherapy for Caregivers to People With Cancer overallStatus: RECRUITING date: 2024-02-29 date: 2029-03-01 date: 2029-03-01 date: 2024-03-13 date: 2024-04-11 name: Memorial Sloan Kettering Cancer Center class: OTHER briefSummary: Participants will complete 1 set of questionnaires about 2 weeks before beginning their Meaning-Centered Psychotherapy for Caregivers/MCP-C or standard Supportive Psychotherapy for Caregivers/SP-C sessions. These questionnaires will ask about participants' sense of meaning and purpose in life, spiritual well-being, depression and/or anxiety, and social support. Participants will then be assigned to receive either MCP-C or SP-C for 7 sessions. Participants will complete additional sets of questionnaires about 2 weeks, 6 months, and 12 months after their last session of MCP-C or SP-C. It will take between 35 and 50 minutes to complete each set of questionnaires.
After participants complete the MCP-C or SP-C sessions and all 4 sets of questionnaires, their participation in this study will end. If participants decide not to complete all 7 sessions, they may still choose to complete the questionnaires.
Participants may remain in the study and continue to receive all 7 sessions of MCP-C or SP-C even if their loved one passes away. conditions: Caregiver Burden conditions: Caregiver Burnout conditions: Caregiver Stress Syndrome studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 200 type: ESTIMATED name: Meaning-Centered Psychotherapy for Caregivers name: Supportive Psychotherapy for Caregivers measure: Number of participants with improved primary outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Miami (Data Collection AND Data Analysis) status: NOT_YET_RECRUITING city: Miami state: Florida zip: 33136 country: United States name: Wendy Lichtenthal, PhD role: CONTACT phone: 305-243-8983 lat: 25.77427 lon: -80.19366 facility: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) status: RECRUITING city: Basking Ridge state: New Jersey zip: 07920 country: United States name: Allison Applebaum, PhD role: CONTACT phone: 646-888-0034 lat: 40.70621 lon: -74.54932 facility: Memorial Sloan Kettering Monmouth (Limited protocol activities) status: RECRUITING city: Middletown state: New Jersey zip: 07748 country: United States name: Allison Applebaum, PhD role: CONTACT phone: 646-888-0034 lat: 40.39652 lon: -74.09211 facility: Memorial Sloan Kettering Bergen (Limited Protocol Activities) status: RECRUITING city: Montvale state: New Jersey zip: 07645 country: United States name: Allison Applebaum, PhD role: CONTACT phone: 646-888-0034 lat: 41.04676 lon: -74.02292 facility: Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) status: RECRUITING city: Commack state: New York zip: 11725 country: United States name: Allison Applebaum, PhD role: CONTACT phone: 646-888-0034 lat: 40.84288 lon: -73.29289 facility: Memorial Sloan Kettering Westchester (Consent only) status: RECRUITING city: Harrison state: New York zip: 10604 country: United States name: Allison Applebaum, PhD role: CONTACT phone: 646-888-0034 lat: 40.96899 lon: -73.71263 facility: Memorial Sloan Kettering Cancer Center status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Allison Applebaum, PhD role: CONTACT phone: 646-888-0034 lat: 40.71427 lon: -74.00597 facility: Memorial Sloan Kettering Nassau (Limited Protocol Activites) status: RECRUITING city: Rockville Centre state: New York zip: 11553 country: United States name: Allison Applebaum, PhD role: CONTACT phone: 646-888-0034 lat: 40.65871 lon: -73.64124 hasResults: False
<\|newrecord\|> nctId: NCT06307522 id: MRG24ALC briefTitle: MRG-001 in Patients With Alcoholic Hepatitis overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2026-09-01 date: 2026-12-01 date: 2024-03-13 date: 2024-03-13 name: MedRegen LLC class: INDUSTRY briefSummary: The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis (AH). conditions: Alcoholic Hepatitis conditions: Acute Alcoholic Hepatitis studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: MRG-001 measure: Assessment of Treatment-Emergent Adverse Events measure: Pharmacokinetic Response measure: Pharmacodynamic Response sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307509 id: GN23AN097 briefTitle: Adiposity and Immunometabolism in Sepsis acronym: AIMS overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-04-30 date: 2025-07-31 date: 2024-03-13 date: 2024-03-13 name: NHS Greater Glasgow and Clyde class: OTHER name: University of Glasgow briefSummary: Obesity has been shown to increase adverse outcomes in some critically ill patients e.g. those with COVID-19. For patients with sepsis this association is less clear cut but there is evidence that body fat distribution, resulting from impaired subcutaneous adipose tissue function, is associated with adverse clinical outcomes in critical care. The investigators aim to study subcutaneous adipose tissue function in lean and obese sepsis patients in critical care and compare that to healthy controls.
First, the study will investigate differences in adipose tissue function (inflammation and mitochondrial function) related to obesity. Second, the investigators will examine whether lean critically ill patients with sepsis have enhanced adipose tissue inflammation and mitochondrial dysfunction compared to lean controls and whether this is further exacerbated by obesity.
Patients will be either undergoing emergency abdominal surgery, or will have been admitted to a critical care unit with a diagnosis of sepsis.
The investigators will collect blood and adipose tissue biopsies from the patients, and these will be analysed for markers of inflammation and of mitochondrial function.
The aim is to better understand the relationship between obesity, inflammation, mitochondrial dysfunction and sepsis. The investigators hope that this may improve the understanding of the pathophysiology of sepsis and allow more targeted interventions for patients based on differences in their baseline metabolic state. conditions: Obesity conditions: Sepsis studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Diagnosis of sepsis measure: Difference in adipocyte cytokine secretion between patients with sepsis, and patients without sepsis, and between SAT and VAT samples measure: Differences in adipocyte size measure: Differences in mitochondrial morphology measure: Differences in adipocyte pro-inflammatory gene expression measure: Differences in adipocyte mitochondrial number measure: Differences in adipocyte mitochondrial viability measure: Differences in SVF cytokine secretion measure: Differences in capacity of pre-adipocytes to differentiate into mature adipocytes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Critical Care Medicine, Queen Elizabeth University Hospital city: Glasgow zip: G51 4TF country: United Kingdom lat: 55.86515 lon: -4.25763 hasResults: False
<\|newrecord\|> nctId: NCT06307496 id: Pro00133913 briefTitle: VIDeOS for Smoking Cessation overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-04 date: 2025-07 date: 2024-03-12 date: 2024-03-12 name: Medical University of South Carolina class: OTHER name: Alliance NCORP Research Base Cancer Control Program briefSummary: The purpose of the current study is to pilot the efficacy, feasibility, and acceptability of an evidence-based smoking cessation intervention adapted for cancer patients and delivered via video. Investigators aim to assess if this intervention is considered acceptable by participants, feasible to implement, and effective at increasing knowledge about smoking cessation before conducting a fully powered clinical trial. conditions: Cancer conditions: Smoking Cessation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 40 type: ESTIMATED name: Smoking cessation intervention name: Informational intervention measure: Acceptability measure: Feasibility measure: Retention Rates measure: Changes in knowledge about quitting smoking measure: Changes in smoking behaviors sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307483 id: 20240108 briefTitle: Dose-effect Relationship of Tai Chi on Health Promotion in Different Age Groups overallStatus: COMPLETED date: 2023-08-25 date: 2023-11-25 date: 2023-11-25 date: 2024-03-12 date: 2024-03-26 name: Beijing Sport University class: OTHER briefSummary: The purpose of this study is to investigate the physical and mental health status of middle-aged and elderly people of different ages and practicing Tai chi for different periods of time, so as to provide a strong theoretical basis and practical guidance for delaying age-related aging and preventing and treating the occurrence and development of chronic diseases. conditions: Sleep Disorder conditions: Cardiovascular Diseases conditions: Hypertension conditions: Cognitive Impairment conditions: Metabolic Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 499 type: ACTUAL name: Taichi group name: Exercise group measure: Pittsburgh Sleep Quality Index measure: Heart rate variability (HRV) measure: Flow-mediated dilation (FMD) measure: Cardiac Output (CO) measure: Intima-Media Thickness (IMT) measure: The Berg Balance Scale（BBS） measure: The 30-s Chair Stand Test measure: Lower limb muscle strength test measure: Body Fat Percentage measure: Finger-Ring Test measure: Hand Grip Strength measure: Upper and Lower Body Flexibility measure: The SARC-F scale measure: Shape Trail Test (STT) measure: 1-back Task more-odd shifting Task Stroop Task measure: Timed Up and Go measure: Close-eyed stepping in place measure: Single-leg stance with eyes closed measure: Ankle-Brachial Index (ABI) measure: Short-Physical Performance Battery (SPPB) measure: Hospital Anxiety and Depression Scale (HADS) measure: Blood pressure variability (BPV) measure: HUR Labs Balance Software Suite measure: E/A ratio measure: Star Excursion Balance Test apparatus（SEBT） measure: Montreal Cognitive Assessment(MoCA) measure: Brachial-ankle pulse wave velocity (BaPWV) sex: ALL minimumAge: 20 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Sport University city: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
<\|newrecord\|> nctId: NCT06307470 id: 276879 briefTitle: Nurse-led Mind-body Intervention on Sexual Health for Breast Cancer Survivors overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-05-30 date: 2024-05-30 date: 2024-03-12 date: 2024-03-20 name: University of Arkansas class: OTHER name: Intimate Pathways Center for Sexual Health briefSummary: The goal of this clinical trial is to test the efficacy of a nurse-led psychoeducational sexual health intervention for young women breast cancer survivors. The main questions it aims to answer are:
1. What is the feasibility of this intervention in an online, private setting?
2. What is the effect of this intervention on reducing menopausal symptoms, improving sexual functioning, and enhancing body image?
Participants will participate in a nurse-led psychoeducational intervention for 8 sessions lasting approximately an hour each over the course of 8 - 10 weeks. Each participant will complete survey items at the beginning, end, and six-weeks after the last session. Participants will be compensated up to $150 in gift cards as a thank-you for their time. conditions: Women's Health: Neoplasm of Breast conditions: Menopause, Premature conditions: Body Image conditions: Sexual Dysfunction conditions: Cancer, Breast studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 42 type: ESTIMATED name: EMBRACE (Empowerment through Mind and Body Reclamation After Cancer Experience) measure: Vulvovaginal Symptoms Questionnaire (VSQ) measure: Body Image Scale measure: Female Sexual Functioning Index sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307457 id: A5481188 briefTitle: A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark. overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-06 date: 2024-08-31 date: 2024-08-31 date: 2024-03-12 date: 2024-03-27 name: Pfizer class: INDUSTRY briefSummary: The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer. The study will consider participants who:
* have advanced or metastatic breast cancer that is spread to other parts of the body.
* have HR+/HER2- (hormone receptor positive\* / human epidermal growth factor receptor 2 negative\\) breast cancer types.
* Hormone receptor positive (HR+): are cells that have a group of proteins that bind to a specific hormone. For example, some breast cancer cells have receptors for the hormones estrogen or progesterone.
These cells are hormone receptor positive, and they need estrogen or progesterone to grow. This can affect how the cancer is treated. Knowing if the cancer is hormone receptor positive may help plan treatment.
* Human epidermal growth factor receptor 2 negative (HER2-): cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Checking to see if a cancer is HER2 negative may help plan treatment.
* have started treatment in the period between January 2017 and December 2021.
The study will describe the treatment effect for different patient groups in terms of age and comorbidities. Comorbidity is the condition of having two or more diseases at the same time. The data is collected by the Danish Breast Cancer Group in the period between 2017 to 2023. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 580 type: ESTIMATED name: Palbociclib in combination with AI measure: Progression-free Survival (PFS) of all mBC patients receiving palbociclib in combination with AI as first-line treatment measure: Overall Survival (OS) of all mBC patients receiving palbociclib in combination with AI as first-line treatment measure: Age distribution in the full data set of mBC patients receiving palbociclib + AI as first-line treatment measure: PFS in mBC patients below 65 years of age receiving palbociclib + AI as first-line treatment measure: PFS in mBC patients between 65-74 years of age receiving palbociclib + AI as first-line treatment measure: PFS in mBC patients 75+ years of age receiving palbociclib + AI as first-line treatment measure: OS in mBC patients below 65 years of age receiving palbociclib + AI as first-line treatment measure: OS in mBC patients between 65-74 years of age receiving palbociclib + AI as first-line treatment measure: OS in mBC patients 75+ years of age receiving palbociclib + AI as first-line treatment measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into Charlson Comorbidity Index (CCI) point score of 0 measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 1 measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 2 measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 3 or higher (3+) measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 0 measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 1 measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 2 measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into CCI point score of 3 or higher (3+) measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment no comorbidity measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment one comorbidity measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment with two or more comorbidities measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment no comorbidity measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment one comorbidity measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment with two or more comorbidities measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Cardiac disease measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Vascular disease measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Metabolic disease measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Psychiatric disease measure: PFS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Blood and lymphatic system measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Cardiac disease measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Vascular disease measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Metabolic disease measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Psychiatric disease measure: OS in the full dataset of mBC patients receiving palbociclib + AI as first-line treatment split into type of comorbidity: Blood and lymphatic system sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Copenhagen University Hospital, Rigshospitalet city: Copenhagen zip: 2100 country: Denmark lat: 55.67594 lon: 12.56553 hasResults: False
<\|newrecord\|> nctId: NCT06307444 id: stellate block and ESP block briefTitle: Ultrasound-Guided Erectro Spinae Plane Block Versus Stellate Ganglion Block for Patients With Upper Limb Acute Herpes Zoster Pain. overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-10-01 date: 2024-11-01 date: 2024-03-12 date: 2024-03-12 name: Tanta University class: OTHER briefSummary: Herpes zoster (HZ) is a painful, eruptive, viral condition results from reactivation of the latent varicella zoster virus after the primary infection. The selection of an effective analgesic method in the acute phase of herpes zoster can decrease the incidence of postherpetic neuralgia by reducing neural sensitization. The stellate ganglion is present in 80% of the general population and is composed of the inferior cervical ganglion and the first thoracic ganglion fusion. It lies anterior to the neck of the first rib and extends to the inferior aspect of the transverse process of C7. The erector spinae plane (ESP) block has been reported to provide diffuse and effective analgesia in the cervical, thoracic, and lumbar regions. conditions: Acute Herpes Zoster Pain Managment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 93 type: ESTIMATED name: Ultrasound-Guided Stellate Ganglion Block name: T2 T3 (High Thorathic) ESP Block measure: reduction of a numeric rating scale (NRS) pain score sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307431 id: V940-004 id: 2023-505177-32 type: OTHER domain: EU CT briefTitle: A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) overallStatus: RECRUITING date: 2024-04-10 date: 2028-01-08 date: 2032-06-08 date: 2024-03-12 date: 2024-04-29 name: Merck Sharp & Dohme LLC class: INDUSTRY name: ModernaTX, Inc. briefSummary: The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS. conditions: Renal Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 272 type: ESTIMATED name: V940 name: Pembrolizumab name: Placebo measure: Disease-Free Survival (DFS) measure: Overall Survival (OS) measure: Distant Metastasis-free survival (DMFS) measure: Percentage of Participants Who Experience an Adverse Event (AE) measure: Percentage of Participants Who Discontinue Study Treatment Due to an AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yale-New Haven Hospital-Yale Cancer Center ( Site 0102) status: RECRUITING city: New Haven state: Connecticut zip: 06510 country: United States name: Study Coordinator role: CONTACT phone: 203-785-5720 lat: 41.30815 lon: -72.92816 facility: Macquarie University-MQ Health Clinical Trials Unit ( Site 1502) status: RECRUITING city: Macquarie University state: New South Wales zip: 2109 country: Australia name: Study Coordinator role: CONTACT phone: +61 2 9812 3526 facility: CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 0008) status: RECRUITING city: Québec state: Quebec zip: G1R 2J6 country: Canada name: Study Coordinator role: CONTACT phone: 4185254444 lat: 46.81228 lon: -71.21454 facility: FALP-UIDO ( Site 1202) status: RECRUITING city: Santiago state: Region M. De Santiago zip: 7500921 country: Chile name: Study Coordinator role: CONTACT phone: 56224457254 lat: -33.45694 lon: -70.64827 facility: ONCOCENTRO APYS-ACEREY ( Site 1200) status: RECRUITING city: Viña del Mar state: Valparaiso zip: 2520598 country: Chile name: Study Coordinator role: CONTACT phone: +56992369820 lat: -33.02457 lon: -71.55183 hasResults: False
<\|newrecord\|> nctId: NCT06307418 id: Carer eSupport RCT briefTitle: Internet-based Support for Informal Caregivers of Patients With Head and Neck Cancer - Carer eSupport overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2025-10-31 date: 2025-10-31 date: 2024-03-12 date: 2024-04-01 name: Uppsala University class: OTHER name: The Swedish Research Council name: Swedish Cancer Society name: Umeå University name: Region Örebro County name: Sahlgrenska University Hospital, Sweden name: University Hospital, Umeå name: Uppsala University Hospital briefSummary: The aim of this randomized controlled trial is to investigate the effects of internet-based support (Carer eSupport) on preparedness for caregiving in informal caregivers of patients with head and neck cancer. The main question\[s\] it aims to answer are:
* What are the effects of internet-based support on informal caregivers preparedness for caregiving?
* What are the effects of internet-based support on informal caregivers burden and wellbeing?
Informal caregivers who are randomized to Carer eSupport will have access to Carer eSupport for 18 weeks and they will be asked to complete questionnaires (outcome measures) at:
* baseline (before randomization)
* 18 weeks (post-intervention) and at
* 3 months after the intervention is completed (long term follow-up).
Informal caregivers in the intervention group will be compared to informal caregivers who receive standard care support regarding preparedness for caregiving, caregiver burden and wellbeing. conditions: Head and Neck Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Informal caregivers of patients with Head and neck cancer will be randomized to internet-based support or to support as usual. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 110 type: ESTIMATED name: Carer eSupport measure: The self-reported questionnaire Preparedness for caregiving scale measure: The self-reported questionnaire Caregiver Burden Scale measure: The self-reported questionnaire Depression Anxiety Stress Scale-21 (DASS21) measure: The self-reported health-related quality of life questionnaire RAND-36 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Örebro University Hospital city: Örebro state: Blekinge Län zip: 70185 country: Sweden lat: 59.27412 lon: 15.2066 facility: Uppsala university hospital city: Uppsala state: Uppsala Län zip: 75105 country: Sweden lat: 59.85882 lon: 17.63889 facility: Norrland University Hospital city: Umeå state: Västerbottens Län zip: 90737 country: Sweden lat: 63.82842 lon: 20.25972 facility: Sahlgrenska university hospital city: Göteborg state: Västra Götaland zip: 41345 country: Sweden lat: 57.70716 lon: 11.96679 hasResults: False
<\|newrecord\|> nctId: NCT06307405 id: WJP2023 briefTitle: The Value of mNGS in Diagnosis of Pulmonary Infection overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-04-20 date: 2025-09-30 date: 2024-03-12 date: 2024-03-12 name: Yunfeng Hou class: OTHER briefSummary: Retrospective analysis of clinical data from 50 hospital-admitted patients with suspected pulmonary infection (as judged by clinical manifestations and imaging findings) was performed on study participants who had collected two different samples of alveolar lavage fluid (BALF) and sputum and underwent metagenomic next generation sequencing (mNGS) and routine pathogen detection, respectively. The positive rate of pathogen detection and the consistency of pathogen detection results of the two detection methods were compared to evaluate the clinical manifestation and role of mNGS in pathogen diagnosis. conditions: Pulmonary Infection studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 50 type: ESTIMATED name: next generation sequencing measure: Etiological detection rates of two detection techniques measure: Consistency of detection results of two detection techniques sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307392 id: RC22_0393 briefTitle: Bougie Versus Endotracheal Tube Alone on First-attempt Intubation Success in Prehospital Emergency Intubation (BETA Trial) acronym: BETA overallStatus: RECRUITING date: 2024-03-26 date: 2027-03-26 date: 2027-03-31 date: 2024-03-12 date: 2024-04-05 name: Nantes University Hospital class: OTHER briefSummary: Emergency intubation is routinely performed in the prehospital setting. Airway management in the prehospital setting has substantial challenges, such as hostile environment or lack of technical support in case of first attempt intubation failure, and inherent risk of complications, such as hypoxemia, aspiration or oesophageal intubation. This risk is higher when several attempts are needed to succeed endotracheal intubation. Thus, a successful first attempt intubation is highly desirable to avoid adverse intubation-related events. Noteworthy, prehospital emergency intubation is associated with a lower rate of first attempt intubation success when compared to emergency intubation in the emergency department (ED). Research is needed to overcome the specific challenges of airway management in the prehospital setting, and to improve the safety and efficiency of prehospital emergency intubation. Literature reports that the use of assistive devices such as bougie may increase the rate of first-attempt intubation success in the ED. To date, no randomized trial has ever studied this device in the prehospital setting. Thus, the aim of the BETA trial is to compare first attempt intubation success facilitated by the bougie versus the endotracheal tube alone in the prehospital setting. conditions: Acute Respiratory Failure Requiring Intubation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 710 type: ESTIMATED name: First intubation attempt with endotracheal tube plus bougie name: First intubation attempt with endotracheal tube alone measure: Number of first pass success during prehospital emergency intubation measure: Occurrence of hypoxia measure: Occurrence of bradycardia measure: Occurrence of cardiac arrest measure: Occurrence of death measure: Occurrence of pulmonary aspirations measure: Occurrence of severe cardiovascular collapse measure: Time between blade introduction to the confirmation of a correct tube placement measure: Change in SpO2 (pulsed oxygen saturation) from the time of induction to lowest SpO2 up to 2 minutes after confirmation of correct tube placement measure: Occurrence of change in SpO2 of more than 3% from the time of induction to 2 minutes after confirmation of correct tube placement measure: Cormack-Lehane grade of glottic view at first intubation attempt measure: Number of laryngoscopies attempts to achieve correct endotracheal tube placement measure: Number of patients for whom the placement of an endotracheal tube was not possible in the pre-hospital setting measure: Difficulty perceived by the operator on first intubation attempt measure: Occurrence of injuries measure: Occurrence of complications measure: Change of SpO2/FiO2 ratio (pulsed oxygen saturation / fraction of inspired oxygen) between the time of confirmation of correct tube placement and the minimum ratio sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nantes University Hospital status: RECRUITING city: Nantes state: Loire Atlantique zip: 44093 country: France name: Quentin Le Bastard, MD role: CONTACT phone: 0240087839 email: quentin.lebastard@chu-nantes.fr name: Quentin Le Bastard, MD role: PRINCIPAL_INVESTIGATOR lat: 47.21725 lon: -1.55336 hasResults: False
<\|newrecord\|> nctId: NCT06307379 id: EC 23022 briefTitle: Patient Reported Outcome and Experience Measures for Bronchoscopic Procedures acronym: BRONCHOPROEM overallStatus: RECRUITING date: 2024-02-13 date: 2025-12-30 date: 2025-12-30 date: 2024-03-12 date: 2024-03-12 name: Vitaz class: OTHER briefSummary: 'Patient-reported outcomes' (PROMS) and 'patient-reported experiences' (PREMS) are increasingly important parameters in evaluating and adjusting clinical procedures and strategies in healthcare.
Validated disease-specific PROMS related to bronchoscopic procedures are not available and examples in the medical literature are very scarce. conditions: Bronchial Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: no intervention measure: Procedure-related dyspnea scale (VAS) measure: Procedure-related pain scale (VAS) measure: Procedure related cough scale (VAS) measure: General patient satisfaction measure: Procedure-related complications: measure: Sedation-related complications measure: Diagnostic yield sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VITAZ status: RECRUITING city: Sint-Niklaas country: Belgium name: Jonas Yserbyt role: CONTACT email: jonas.yserbyt@vitaz.be lat: 51.16509 lon: 4.1437 hasResults: False
<\|newrecord\|> nctId: NCT06307366 id: ErasmusMC10365 briefTitle: Perceptions and Experiences of (Family Members of) People With Mental Illness About the Chance for Mental Illness in (Future) Children, and Needs for Care and Research acronym: PANDAcc overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2024-06 date: 2024-03-12 date: 2024-03-12 name: Erasmus Medical Center class: OTHER briefSummary: Despite consistent evidence that mental illness runs in families, intergenerational transmission of risk of mental illness is rarely considered in clinical practice. Neither preventive programs for children of parents with mental illness are usually implemented in care, nor supportive programs for parenting. Furthermore, parents with mental illness are not always aware of how their disorder may impact the well-being of their children. To date, the needs for counseling, care and research in parents with mental illness and family members of people with mental illness are unclear. Therefore, this prospective qualitative interview study aims to gain insights into the perceptions and experiences of (future) parents with mental illness, partners and family members of people with mental illness about risk for and resilience against mental illness in (future) children, as well as their needs for counseling, care and research. conditions: Mental Illness studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 10 type: ESTIMATED name: No intervention will be used measure: Themes around the topics (related to perceptions and experiences) explored. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus Medical Center city: Rotterdam state: Zuid-Holland zip: 3000CB country: Netherlands name: Lisanne AE van Houtum, PhD role: CONTACT phone: +31107037005 email: l.vanhoutum@erasmusmc.nl name: Hilmar H Bijma, MD, PhD role: CONTACT phone: +31107036109 email: h.bijma@erasmusmc.nl name: Hilmar H Bijma, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Neeltje EM van Haren, PhD role: SUB_INVESTIGATOR name: Lisanne AE van Houtum, PhD role: SUB_INVESTIGATOR name: Eline MP Poels, MD, PhD role: SUB_INVESTIGATOR lat: 51.9225 lon: 4.47917 hasResults: False
<\|newrecord\|> nctId: NCT06307353 id: Soh_Med_23_12_05MS briefTitle: Trends of Contraception Methods in Urban Medical Center in el_Balyana overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-10-01 date: 2025-03-01 date: 2024-03-12 date: 2024-03-12 name: Sohag University class: OTHER briefSummary: family planning is avital primary Health care intervention that saves lives of mothers and infants empowers women and support their choices regarding their health public life and additional education .In addition family planning is considered as a short term intervention to limit population growth and manage overpopulation problems.Globally the contraception prevalance rate an indicator for family planning programs continue to face challenges in developing countries. conditions: Contraception studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 385 type: ESTIMATED name: trends of contraception methods measure: number of married women in child bearing period attending the El_Balyana Medical Center using contraception methods . sex: FEMALE minimumAge: 15 Years maximumAge: 49 Years stdAges: CHILD stdAges: ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307340 id: 22-01058 briefTitle: Adaption of the STAIR-NT Trauma Intervention for Polysubstance Populations overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-10 date: 2024-03-12 date: 2024-04-04 name: NYU Langone Health class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: During this 36-month R34 trial, eight study phases are proposed to adapt an evidence-based post traumatic stress disorder (PTSD) intervention (STAIR-NT) and layer it into a methadone maintenance treatment (MMT) program (START Treatment and Recovery centers) in New York City for use among individuals engaged in stimulant-opioid polysubstance use. The study aims to adapt STAIR-NT to a massed treatment schedule. Once an adapted protocol is complete, it will be tested for feasibility, acceptability, and short-term polysubstance and PTSD symptomology outcomes in a pilot randomized control trial (RCT) of 80 participants. Participants who screen eligible and consent will be randomized 1:1 to the adapted STAIR-NT intervention or treatment as usual (TAU) using randomization blocks of two and two and four via a computer-generated randomization sequence. Participants assigned to the intervention will receive the adapted massed delivery of STAIR-NT by trained counselors. conditions: Polysubstance Abuse conditions: Posttraumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE maskingDescription: The data analyst is blinded to participant arm. whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Skills Training in Affective and Interpersonal Regulation with Narrative Therapy (STAIR-NT) name: Treatment as Usual measure: Proportion of Eligible Participants measure: Proportion of Eligible Participants who Enroll measure: Number of Intervention Sessions Completed measure: Clinician-Rated Feasibility of Intervention Measure (FIM) Score measure: Clinician-Rated Feasibility of Acceptability of Intervention Measure (AIM) Score measure: Number of Days of Co-Use of Cocaine and Illicit Opioids measure: Number of Substances Used based on ASI Self-Report measure: Number of Substances Used based on Urine Drug Screen measure: Number of Substances Used based on Chart Abstraction of Toxicology Results measure: PTSD Checklist for DSM-5 (PCL-5) Score measure: Negative Mood Regulation Scale Score measure: Inventory of Interpersonal Problems Score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Florida State University city: Tallahassee state: Florida zip: 32306 country: United States name: Tanya Renn, PhD role: PRINCIPAL_INVESTIGATOR lat: 30.43826 lon: -84.28073 facility: START Treatment and Recovery Centers city: Brooklyn state: New York zip: 11238 country: United States name: Ana Ventuneac role: PRINCIPAL_INVESTIGATOR lat: 40.6501 lon: -73.94958 facility: NYU Langone Health city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
<\|newrecord\|> nctId: NCT06307327 id: NFEC-2024-098 briefTitle: Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis overallStatus: RECRUITING date: 2024-03 date: 2025-12 date: 2026-12 date: 2024-03-12 date: 2024-03-26 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: Radiation oropharyngeal mucositis is one of the most painful side effects of radiotherapy in patients with head and neck tumors. However, the traditional radioactive oropharyngeal mucositis grading system has the problem of poor evaluation consistency. To solve this problem, we innovatively classify radiation oropharyngeal mucositis into four types according to the four-stage histopathological changes of acute radiation injury: (1) congestive; (2) Scattered erosion type; (3) Fusion erosion type; (4) Ulcer type. We intend to conduct a multicenter observational cohort study to compare the consistency of different physicians in the assessment of radiation oropharyngeal mucositis with new and traditional classifications, and to explore changes in blood markers of different types of oropharyngeal mucositis using clinical residual blood samples. conditions: Head and Neck Cancer conditions: Radiation-Induced Mucositis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 894 type: ESTIMATED measure: Evaluation consistency sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Southern medical university status: RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Jian Guan, M.D role: CONTACT phone: 86+13632102247 email: guanjian5461@163.com lat: 23.11667 lon: 113.25 facility: Huizhou Central People's Hospital status: NOT_YET_RECRUITING city: Huizhou state: Guangdong zip: 516000 country: China name: Yunming Tian role: CONTACT lat: 23.11147 lon: 114.41523 facility: Jieyang people's hospital status: NOT_YET_RECRUITING city: Jieyang state: Guangdong zip: 522000 country: China name: Peibao Lai role: CONTACT phone: 86+15975196057 email: boa71@139.com lat: 23.5418 lon: 116.36581 facility: Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou status: NOT_YET_RECRUITING city: Meizhou state: Guangdong zip: 514000 country: China name: Jianda Sun role: CONTACT lat: 24.2886 lon: 116.11767 hasResults: False
<\|newrecord\|> nctId: NCT06307314 id: NFEC-2024-093 briefTitle: Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis overallStatus: RECRUITING date: 2024-02-01 date: 2026-12-01 date: 2026-12-31 date: 2024-03-12 date: 2024-03-12 name: Nanfang Hospital, Southern Medical University class: OTHER briefSummary: Head and neck squamous cell carcinoma (SCC) is the sixth most common cancer worldwide, with more than 700,000 new cases and more than 350,000 deaths each year. At present, radiotherapy is an important measure to control the recurrence of head and neck tumors, but almost all patients with head and neck squamous cell carcinoma will have acute inflammatory reactions such as radiotherapy-induced oral mucositis (RIOM) after radiotherapy, which seriously affects the quality of life and radiotherapy efficacy of patients. Serum amyloid A1 (SAA1) is an acute phase protein associated with inflammation. Our previous basic research found that serum SAA1 expression levels can be used as biomarkers to assess the dose received by the receptor in the early stages of radiation damage. At the same time, we confirmed that the serum level of SAA1 in patients with nasopharyngeal carcinoma increased after radiotherapy. Therefore, we intend to conduct a prospective, multicenter, observational study to further explore the predictive power of plasma SAA1 levels for radiotherapy-induced oral mucositis, with a view to early screening and prevention of RIOM patients. conditions: Nasopharyngeal Carcinoma conditions: Head and Neck Cancer conditions: Radiotherapy-induced Oral Mucositis conditions: Biomarker studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: Different grades radiotherapy-induced oral mucositis measure: Start and duration of radiotherapy-induced oral mucositis measure: Side effects of radiotherapy measure: Tumor response sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanfang hospital, Southern medical university status: RECRUITING city: Guangzhou state: Guangdong zip: 510515 country: China name: Jian Guan, Ph.D. role: CONTACT lat: 23.11667 lon: 113.25 facility: Fujian Provinical Hospital status: NOT_YET_RECRUITING city: Fuzhou country: China name: Yongmei Dai role: CONTACT lat: 26.06139 lon: 119.30611 facility: Huizhou Central People's Hospital status: NOT_YET_RECRUITING city: Huizhou country: China name: Yunming Tian role: CONTACT lat: 23.11147 lon: 114.41523 facility: Jieyang People's Hospital status: NOT_YET_RECRUITING city: Jieyang country: China name: Peibao Lai role: CONTACT lat: 23.5418 lon: 116.36581 facility: Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou status: NOT_YET_RECRUITING city: Meizhou country: China name: Jianda Sun role: CONTACT lat: 24.2886 lon: 116.11767 hasResults: False
<\|newrecord\|> nctId: NCT06307301 id: PRO00031998 briefTitle: Study in ALS With Abatacept & IL-2 overallStatus: ACTIVE_NOT_RECRUITING date: 2021-10-28 date: 2024-10-17 date: 2024-10-17 date: 2024-03-12 date: 2024-04-16 name: The Methodist Hospital Research Institute class: OTHER briefSummary: In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T-lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. The investigator completed a phase 1 study of infusions of expanded autologous Tregs in combination with subcutaneous IL-2 injections in ALS patients, which showed enhancement of Treg numbers and suppressive function in vivo. The enhanced Treg suppressive function correlated strongly with slowing and stabilization of disease progression. Drugs that enhance endogenous Treg numbers and suppressive function may also stabilize disease in ALS. This phase 1 study aims to determine whether the combination therapy of subcutaneous IL-2 and abatacept (Orencia®) is safe and well-tolerated in 6 patients with ALS, and whether the therapy enhances Treg numbers and suppressive function in vivo. conditions: Amyotrophic Lateral Sclerosis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 5 type: ACTUAL name: Abatacept Injection [Orencia] and Proleukin (aldesleukin) measure: To evaluate adverse events and laboratory abnormalities to assess the safety and tolerability of abatacept followed by Interleukin 2 (IL-2) administration in ALS patients measure: Change in Regulatory T cells (Tregs) numbers in the blood from baseline measure: Change in Regulatory T cells (Tregs) suppressive function in the blood from baseline measure: Changes in the level of cytokines secreted by PBMCs from baseline measure: Changes in Appel Amyotrophic Lateral Sclerosis rating scale ( AALS) slope measure: Changes in Amyotrophic Lateral Sclerosis functional rating scale-revised (ALSFRS-R) slope measure: Changes in forced vital capacity (FVC) and maximum inspiratory pressure (MIP) scores measure: Changes in maximum inspiratory pressure (MIP) scores sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Houston Methodist Research Institute city: Houston state: Texas zip: 77030 country: United States lat: 29.76328 lon: -95.36327 hasResults: False
<\|newrecord\|> nctId: NCT06307288 id: 20240301-2 briefTitle: Efficacy and Safety of Tranilast Combined With Minocycline in the Treatment of Rosacea overallStatus: ENROLLING_BY_INVITATION date: 2023-10-16 date: 2024-06-01 date: 2024-06-01 date: 2024-03-12 date: 2024-03-12 name: Second Affiliated Hospital of Xi'an Jiaotong University class: OTHER briefSummary: Rosacea is a chronic inflammatory skin disease with a complex pathogenesis involving multiple factors. Currently, the treatment of rosacea remains highly challenging. Mast cells, as key participants in the pathogenesis of rosacea, have been shown to alleviate rosacea symptoms with some topical, oral, and injectable mast cell stabilizers in recent years. Tranilast stabilizes mast cells and basophils by acting on their cell membranes and preventing their degranulation. Tranilast has been used in the treatment of various skin disease, such as hypertrophic scars and atopic dermatitis. Minocycline is a first-line treatment for rosacea, and low-dose minocycline treatment (50mg/day) is believed to have anti-inflammatory effects without antibacterial effects, thus minimizing the dysbiosis and bacterial resistance caused by antibiotic use. Therefore, this study aims to investigate the effectiveness and safety of combining mast cell stabilizer tranilast with low-dose minocycline treatment for rosacea, providing new treatment options and insights for rosacea patients. conditions: Rosacea studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: minocycline name: tranilast measure: lesion counts measure: Clinician's Erythema Assessment score measure: Global Flushing Severity Scale score measure: Global Acne Grading System score measure: patient satisfaction evaluation measure: melanin index measure: erythema index measure: transepidermal water loss measure: Dermatology Life Quality Index score sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: The Second Affiliated Hospital of Xi'an Jiaotong Universi city: Xi'an state: Shaanxi zip: 710000 country: China lat: 34.25833 lon: 108.92861 hasResults: False
<\|newrecord\|> nctId: NCT06307275 id: 5170221 briefTitle: Intermittent Fasting on Body Fat and Quality of Life overallStatus: RECRUITING date: 2024-03-11 date: 2024-12-31 date: 2024-12-31 date: 2024-03-12 date: 2024-04-12 name: Loma Linda University class: OTHER briefSummary: The purpose of this investigator-initiated study to check the feasibility that intermittent fasting has on body fat loss and quality of life. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 70 type: ESTIMATED name: Fasting name: non fasting measure: Body fat percentage measure: Visceral fat sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Loma Linda University status: RECRUITING city: Loma Linda state: California zip: 92350 country: United States name: Gurinder Bains, PhD role: CONTACT phone: 909-558-4000 phoneExt: 87274 email: gbains@llu.edu lat: 34.04835 lon: -117.26115 hasResults: False
<\|newrecord\|> nctId: NCT06307262 id: EuroTR Registry briefTitle: European Registry of Transcatheter Repair for Tricuspid Regurgitation acronym: EuroTR overallStatus: RECRUITING date: 2023-10-23 date: 2030-12-31 date: 2030-12-31 date: 2024-03-12 date: 2024-03-15 name: LMU Klinikum class: OTHER briefSummary: To investigate clinical and survival outcomes following transcatheter tricuspid valve repair or replacement. conditions: Tricuspid Regurgitation conditions: Valvular Heart Disease conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 3000 type: ESTIMATED name: T-TEER measure: All-cause mortality measure: Technical success measure: Procedural Safety measure: Heart Failure Biomarker measure: Dyspnea on exertion measure: Functional capacity measure: Right ventricular size measure: Right ventricular function measure: Tricuspid regurgitation reduction measure: Tricuspid valve stenosis measure: Pulmonary hypertension measure: Right heart congestion measure: Hospitalization for heart failure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: LMU Klinikum status: RECRUITING city: Munich state: Bavaria zip: 81377 country: Germany name: Jörg Hausleiter, Prof. Dr. role: CONTACT phone: +49 89 4400 72360 email: Joerg.Hausleiter@med.uni-muenchen.de name: Lukas Stolz, Dr. role: CONTACT email: Lukas.Stolz@med.uni-muenchen.de lat: 48.13743 lon: 11.57549 hasResults: False
<\|newrecord\|> nctId: NCT06307249 id: LU_HH_Cancer_Precision Therapy briefTitle: Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA acronym: PTST_PALBEVA overallStatus: RECRUITING date: 2023-02-15 date: 2025-12 date: 2027-12 date: 2024-03-12 date: 2024-03-12 name: Lebanese University class: OTHER name: Haykel Hospital briefSummary: Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects. This clinical trial focuses on an innovative combination of two targeted inhibitors, Palbociclib and Bevacizumab, for their potential synergistic effects in addressing these challenging malignancies. Moreover, this study incorporates a molecular approach by considering Long Non-Coding RNAs (LncRNAs) as biomarkers. Initiating with a focus on colorectal cancer, the study aims to expand its scope to other solid tumors, including lung, breast, ovarian and other cancers. Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, disrupts the cell cycle progression, particularly in cancer cells with specific molecular characteristics. Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, targets angiogenesis-a critical process for tumor growth and metastasis. The rationale behind combining these agents lies in their complementary mechanisms of action, potentially leading to enhanced antitumor effects. LncRNAs have shown promise in predicting treatment response and prognosis in various cancers, providing an additional layer of precision to the treatment strategy. By elucidating the molecular basis through LncRNA analysis, the trial aims to tailor the treatment to the specific molecular profile of each patient, ultimately striving for better outcomes and improved survival rates. This novel combination therapy, coupled with a personalized biomarker-driven approach, represents a cutting-edge strategy in the pursuit of more effective and individualized treatment for solid tumors. conditions: Cancer conditions: Solid Tumor conditions: Colorectal Cancer conditions: Breast Cancer conditions: Ovarian Cancer conditions: Lung Cancer conditions: Targeted Therapy conditions: Chemotherapy conditions: Immunotherapy conditions: Precision Therapy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 50 type: ESTIMATED name: SNP name: Palbociclib 125mg name: Bevacizumab measure: Assessment of Cancer Progression measure: Identification of Potential Biomarkers measure: Evaluation of Treatment Response to Palbociclib and Bevacizumab Combination Therapy measure: Survival Rates measure: Adverse Events measure: Assessment of Immune Checkpoint Expression (e.g., PD-1 and CTLA-4) measure: Measurement of Angiogenic Factors (e.g., VEGF) measure: Measurement of Tumor Proliferation Markers (e.g., Ki67, P16) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Haykel Hospital status: RECRUITING city: Tripoli state: North Lebanon zip: 961 country: Lebanon name: David Wehbe, MD role: CONTACT email: Wehbehdavid@hotmail.com name: Malak Naboulsi, PharmD role: CONTACT email: malak.naboulsi@gmail.com lat: 34.43667 lon: 35.84972 facility: Lebanese University status: RECRUITING city: Tripoli state: North Lebanon zip: 961 country: Lebanon name: Neham Makdissy, Professor role: CONTACT phone: 71210250 phoneExt: +961 email: nehman.makdissy@ul.edu.lb name: Samar Hamoui, PhD role: SUB_INVESTIGATOR name: Fida Ayoubi, PhD role: SUB_INVESTIGATOR name: Nouha Ibrahim, PhD role: SUB_INVESTIGATOR name: Nadine Ghotme, PhD role: SUB_INVESTIGATOR name: Elisa Makdessi, PhD Student role: SUB_INVESTIGATOR lat: 34.43667 lon: 35.84972 hasResults: False
<\|newrecord\|> nctId: NCT06307236 id: E-41997688-050.99-105442 briefTitle: Dysmenorrhea of Emotional Freedom Techniques (EFT) and Its Effect on Perceived Stress Level overallStatus: ENROLLING_BY_INVITATION date: 2023-12-15 date: 2024-04-15 date: 2024-04-15 date: 2024-03-12 date: 2024-03-12 name: Kutahya Health Sciences University class: OTHER briefSummary: The aim of the study is to determine the effect of EFT application on the level of dysmenorrhea and stress perception in women with dysmenorrhea. For this purpose, EFT will be applied to women with dysmenorrhea with high stress perception assigned to the experimental and control groups, and their stress perceptions and dysmenorrhea levels will be re-evaluated after the application. Perceived Stress Scale (PSS) and Visual Analog Scale (VAS) will be used in the research. conditions: Dysmenorrhea Primary conditions: Stress conditions: Emotional Freedom studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Study primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Single Blinded whoMasked: PARTICIPANT count: 56 type: ESTIMATED name: Emotional Freedom Techniques measure: EFT application measure: Control sex: FEMALE minimumAge: 18 Years maximumAge: 49 Years stdAges: ADULT facility: Kütahya Health Science University city: Kütahya zip: 43000 country: Turkey lat: 39.42417 lon: 29.98333 hasResults: False
<\|newrecord\|> nctId: NCT06307223 id: 20240301 briefTitle: Efficacy and Safety of 30% Supramolecular Salicylic Acid Combined With Supramolecular Active Zinc in the Treatment of Malassezia Folliculitis overallStatus: COMPLETED date: 2022-06-07 date: 2023-09-20 date: 2023-09-20 date: 2024-03-12 date: 2024-03-12 name: Second Affiliated Hospital of Xi'an Jiaotong University class: OTHER briefSummary: Malassezia folliculitis is a common dermatological disorder. While antifungal agents generally demonstrate efficacy in application, the prevalence of recurrence and drug resistance remains a common occurrence. Supramolecular salicylic acid represents a novel class of superficial chemical peel agents, exhibiting keratolytic, anti-inflammatory, and bacteriostatic properties. Zinc pyrithione has broad spectrum antibacterial, antifungal, and anti-inflammatory effects. In the present study, investigators evaluated the clinical efficacy of topical application of supramolecular salicylic acid in combination with zinc pyrithione for the treatment and prevention of Malassezia folliculitis recurrence. All data are recorded and compared after the end of the experiment. The enrolled patients received daily application of topical supramolecular active zinc anti-dandruff lotion, in conjunction with weekly application of 30% supramolecular salicylic acid, for a duration of 8 weeks. Lesion counts, Malassezia detection, clinical symptom scores, patient satisfaction, and side effects were recorded at each visit till the week 12. conditions: Malassezia Folliculitis studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 21 type: ACTUAL name: 30% supramolecular salicylic acid name: supramolecular active zinc measure: lesion counts measure: The reduction rate of lesion counts measure: Clinical efficacy measure: Clinical symptoms scores sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Xi'an Jiaotong University city: Xi'an state: Shaanxi zip: 710000 country: China lat: 34.25833 lon: 108.92861 hasResults: False
<\|newrecord\|> nctId: NCT06307210 id: coreset_2020_2022 briefTitle: Is Inpatient Rehabilitation Effective for Very Old Patients? overallStatus: COMPLETED date: 2020-01-01 date: 2022-12-31 date: 2023-01-01 date: 2024-03-12 date: 2024-03-12 name: Klinik Valens class: OTHER briefSummary: The goal of this retrospective longitudinal observational study is to compare the effects of physical and mental performance as well as quality of life in patients with neurological and musculoskeletal disorders.
The main question it aims to answer is: Do very old patients benefit in a similar way from inpatient rehabilitation like younger patients? Data from about 2000 patients will be retrospectively analyzed. Functional Independence Measurement (FIM), Timed Up and Go Test (TUG), EuroQol 5 Dimensions (EQ-5D) and Patient Reported Outcomes Measurement Information System (PROMIS) were recorded on admission and discharge.
Researchers will compare the age group 75 to 84 and 85 to 99 to see if physical and mental performance as well as quality of life will improve. conditions: Activity, Motor conditions: Elderly Patients conditions: Musculoskeletal Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 2270 type: ACTUAL name: inpatient rehabilitation measure: FIM measure: TUG measure: EQ-5D (Quality of life) measure: PROMIS sex: ALL minimumAge: 75 Years maximumAge: 100 Years stdAges: OLDER_ADULT facility: Klinik Valens city: Valens state: Saint Gallen zip: CH-7317 country: Switzerland lat: 46.96658 lon: 9.47705 hasResults: False
<\|newrecord\|> nctId: NCT06307197 id: INRCA_008_2023 briefTitle: HAAL: HeAlthy Ageing Eco-system for peopLe With Dementia acronym: HAAL overallStatus: RECRUITING date: 2023-10-02 date: 2024-04-15 date: 2024-04-15 date: 2024-03-12 date: 2024-03-12 name: Istituto Nazionale di Ricovero e Cura per Anziani class: OTHER briefSummary: HAAL project aims to test several technological devices in order to improve the quality of life of older people with dementia and their informal and formal caregiver. conditions: Dementia conditions: Devices conditions: Artificial Intelligence conditions: Older People conditions: Caregiver Burden studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 10 type: ESTIMATED name: HAAL platform measure: Care load of caregivers sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: IRCCS INRCA Hospital status: RECRUITING city: Ancona country: Italy name: Elvira Maranesi role: CONTACT email: e.maranesi@inrca.it name: Roberta Bevilacqua role: PRINCIPAL_INVESTIGATOR lat: 43.5942 lon: 13.50337 hasResults: False
<\|newrecord\|> nctId: NCT06307184 id: 2301-LIS-007-AN briefTitle: Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer overallStatus: RECRUITING date: 2024-02-23 date: 2024-10 date: 2025-07 date: 2024-03-12 date: 2024-03-12 name: Instituto Valenciano de Infertilidade de Lisboa class: NETWORK name: Gedeon Richter Ltd. briefSummary: This study will assess the convenience of the natural proliferative phase frozen embryo transfer (NPP-FET) in terms of number of number of appointments needed before cycle scheduling. conditions: Frozen Embryo Transfer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 530 type: ESTIMATED name: Natural proliferative phase frozen embryo transfer measure: Number of appointments needed before cycle scheduling measure: Cycle duration until embryo transfer (days) measure: Proportion of patients with low progesterone values on the day of embryo transfer measure: Human corionic gonadotropin (hCG) positive rate measure: Miscarriage rate measure: Ongoing pregnancy rate measure: Live birth rate measure: Serum Relaxin-2 levels measure: Serum Luteinizing Hormone (LH) levels sex: FEMALE minimumAge: 18 Years maximumAge: 49 Years stdAges: ADULT facility: Instituto Valenciano de Infertilidade status: RECRUITING city: Lisboa country: Portugal name: Samuel Santos-Ribeiro, MD PhD role: CONTACT lat: 38.71667 lon: -9.13333 hasResults: False
<\|newrecord\|> nctId: NCT06307171 id: 2023-11 briefTitle: Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers acronym: LeishmARPs overallStatus: RECRUITING date: 2023-05-22 date: 2026-11 date: 2026-11 date: 2024-03-12 date: 2024-03-12 name: IRCCS Sacro Cuore Don Calabria di Negrar class: OTHER briefSummary: This is an exploratory experimental multicentre study on archived serum samples and on prospectively collected serum samples and blood samples.
General objectives of the study are: to identify specific biomarkers in order to develop more accurate serological tests for the screening of Leishmania infections that does not present cross-reaction with other infectious diseases; to unveil the Antigen Recognition Patterns (ARPs) of Leishmania infection in humans; to verify whether the ARPs and the new biomarkers are common to different Leishmania infantum strains isolated in Italy as well as in other part of the World and to different strains of L. donovani isolated in Sudan as well as in other part of the World and discard any possible cross reaction with other infectious diseases such as Chagas, TB, leprosy or malaria. conditions: Leishmaniasis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 170 type: ESTIMATED name: In-house Western blot, specific for Leishmania measure: Biomarkers from Leishmania spp measure: ARPs in different Leishmania infantum and L. donovani strains measure: Cross reaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Sacro Cuore Don Calabria hospital status: RECRUITING city: Negrar state: Verona zip: 37024 country: Italy name: Silvia Longoni role: CONTACT phone: +390456013111 email: silvia.longoni@sacrocuore.it name: Silvia Longoni role: PRINCIPAL_INVESTIGATOR lat: 45.52918 lon: 10.93899 hasResults: False
<\|newrecord\|> nctId: NCT06307158 id: CT2024-ZJU-OBS1 briefTitle: Influence of Intraoperative Blood Salvage and Autotransfusion on Tumor Recurrence After Deceased Donor Liver Transplantation overallStatus: COMPLETED date: 2015-01-01 date: 2020-12-31 date: 2021-12-31 date: 2024-03-12 date: 2024-03-12 name: Zhejiang University class: OTHER name: Shulan (Hangzhou) Hospital briefSummary: The practice of intraoperative blood salvage and autotransfusion (IBSA) during deceased donor liver transplantation (DDLT) for hepatocellular carcinoma (HCC) can potentially reduce the need for allogeneic blood transfusion. However, implementing IBSA remains debatable due to concerns about its possible detrimental effects on oncologic recurrence. Hence, a nationwide multi-center study was conducted to investigate further the association between IBSA and post-transplant HCC recurrence, including a stratified subgroup analysis. conditions: Liver Transplant; Complications studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 998 type: ACTUAL measure: Postoperative recurrence of liver cancer sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307145 id: K-NHIS-HIP briefTitle: Korea Hip Replacement Surgery Registry overallStatus: COMPLETED date: 2003-01-01 date: 2020-12-31 date: 2020-12-31 date: 2024-03-12 date: 2024-03-12 name: Samsung Medical Center class: OTHER briefSummary: This cohort study obtained data from the Korean National Health Insurance Service (K-NHIS) database. For the hip replacement registry, we included all adult patients older than 19 who received total or hemiarthroplasty surgery between January 1, 2003, and December 31, 2019. Using this registry, we compared efficacy and safety by type of head or liner. conditions: Hip Replacement Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 124556 type: ACTUAL measure: Cancer sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06307132 id: SAHoWMU-CR2024-03-106 briefTitle: Drug Metabolism, Excretion, and Human Body Composition of Aximus Capsules overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-31 date: 2024-06-30 date: 2024-08-31 date: 2024-03-12 date: 2024-03-12 name: Second Affiliated Hospital of Wenzhou Medical University class: OTHER briefSummary: This project will be based on the bioequivalence test of Aximus capsules, measuring the body composition indicators of healthy subjects before and after medication, and collecting urine samples from subjects at different time periods after medication, measuring urine drug concentration, calculating urine excretion, analyzing the individualized differences in metabolism and excretion of Aximus capsules under different health states of human components, and providing guidance for clinical precision medication. conditions: Bioequivalence Trial studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 26 type: ESTIMATED name: Aximus capsules（test） name: Aximus capsules（reference） measure: Excretion volume sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: The Second Affiliated Hospital of WMU Phase l Clinical Trial Unit /Center Of Bioequivalence Study city: Wenzhou country: China lat: 27.99942 lon: 120.66682 hasResults: False
<\|newrecord\|> nctId: NCT06307119 id: 2020-01 briefTitle: Model of Human Occupation-Based Intervention on Premenstrual Syndrome Symptoms overallStatus: COMPLETED date: 2023-03-01 date: 2024-03-01 date: 2024-03-02 date: 2024-03-12 date: 2024-03-12 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: This study was conducted to examine the effect of two different occupational therapy interventions on premenstrual syndrome symptoms in university students. This study was designed according to the CONSORT statement, which provides a standard method for randomised controlled trial (RCT) design. The study was approved by the Local Ethics Committee. Written informed consent was obtained from all participants before the study. conditions: Premenstrual Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 95 type: ACTUAL name: Occupational Therapy and Relaxation Group name: Relaxation Group measure: Occupational Self-Assessment measure: The Model of Human Occupation Screening Tool (MOHOST) measure: Premenstrual Symptom Screening Tool sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Health Sciences Turkey city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
<\|newrecord\|> nctId: NCT06307106 id: #40\14-Jan-2024 briefTitle: Various Strategies to Reduce Acute Post Hemorrhoidectomy Pain: A Comparative Study overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-14 date: 2024-07-14 date: 2024-07-14 date: 2024-03-12 date: 2024-03-12 name: Zagazig University class: OTHER_GOV briefSummary: Since post hemorrhoidectomy pain is a severe and common post operative symptom so there is a need to find a suitable method for reducing this pain, up to our knowledge, this the first study in ZUH to compare between ketrolac, light Marcaine, corticosteroids and diclofenac sodium injection at surgical site for relieve of post operative pain. This is a randomizes comparative prospective clinical trial. conditions: Acute Post Operative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 120 type: ACTUAL name: ketorolac and light marcaine name: light marcaine name: Corticosteroids injection name: Diclofenac Sodium Gel measure: age measure: sex measure: number of hemorrhoids measure: degree of hemorroids measure: post operative pain measure: ambulation measure: return to work measure: patient satisfaction sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Zagazig University Hospitals city: Zagazig zip: 44519 country: Egypt lat: 30.58768 lon: 31.502 hasResults: False
<\|newrecord\|> nctId: NCT06307093 id: CL01860198 briefTitle: Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms overallStatus: ACTIVE_NOT_RECRUITING date: 2023-03-01 date: 2023-12-11 date: 2025-07 date: 2024-03-12 date: 2024-03-12 name: R-Pharm class: INDUSTRY name: Data Management 365 name: Exacte Labs LLC name: Federal State Budgetary Institution "NMIC of Hematology" of the Ministry of Health of the Russian Federation name: Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor briefSummary: The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and pharmacodynamics of the drug RPH-075 (international nonproprietary name (INN) is pembrolizumab) in comparison with the drug Keytruda® (INN is pembrolizumab) after a single intravenous injection to patients with malignant neoplasms as a first or second line therapy in a monotherapy regimen.
The main main tasks are:
* To evaluate and compare the pharmacokinetic properties of RPH-075 and Keytruda® after a single intravenous administration of pembrolizumab to patients with malignant neoplasms;
* To evaluate the safety profile of the drug RPH-075 in comparison with the drug Keytruda® when used in patients with malignant neoplasms when used as a 1st or 2nd line therapy in a monotherapy regimen.

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.